47. Solomon SD, Zelenkofské S, McMurray JJV, Finn PV, Velazquez E, Ertl G, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581-8. https://doi.org/10.1056/NEJMoa043938

48. Gula LJ, Klein GJ, Hellkamp AS, Massel D, Krahn AD, Skanes AC, et al. Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2008;156:1196-200. https://doi.org/10.1016/j.ahj.2008.08.007

49. Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC: Heart Fail. 2016;5:28-38. https://doi.org/10.1016/j.j.2016.09.017

50. Coleman GC, Shaw PW, Balfour PC, Gonzalez JA, Kramer CM, Patel AR, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis. JACC: Cardiovasc Imaging. 2017;10(4):411-20. https://doi.org/10.1016/j.jcmg.2016.05.009

51. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC: Cardiovasc Imaging. 2013;6(4):501-11. https://doi.org/10.1016/j.jcmg.2012.10.021

52. Naruse Y, Sekiguchi Y, Nogami A, Okada H, Yamauchi Y, Machino T, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2014;7:407-13. https://doi.org/10.1161/CIRCEP.113.000734

53. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329-36. https://doi.org/10.1016/j.jacc.2013.09.022

54. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933-40. https://doi.org/10.1056/NEJM199612263352601

55. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83. https://doi.org/10.1056/NEJMoa013474

56. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37. https://doi.org/10.1056/NEJMoa043399

57. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110:3760-5. https://doi.org/10.1161/01.CIR.0000150390.04704.B7

58. Stecker EC, Vickers C, Waltz J, Socoteanu C, John BT, Mariani R, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol. 2006;47:1161-6. https://doi.org/10.1016/j.jacc.2005.11.045

59. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A. Wellens HJ. Out-of-hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J. 2003;24:1204-9. https://doi.org/10.1016/S0195-668X(03)00191-X

60. Stevens SM, Reinier K, Chugh SS. Increased left ventricular mass as a predictor of sudden cardiac death: is it time to put it to the test? Circ Arrhythm Electrophysiol. 2013;6:212-7. https://doi.org/10.1161/CIRCEP.112.974931

61. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221-30. https://doi.org/10.1056/NEJMoa1608029

62. Piers SRD, Tao Q, van Huls van Taxis CFB, Schalij MJ, van der Geest RJ, Zeppenfeld K. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6:875-3. https://doi.org/10.1161/CIRCEP.113.000537

63. White JA, Fine NM, Gula L, Yee R, Skanes A, Klein G, et al. Utility of cardiovascular magnetic resonance in identifying substrate for malignant ventricular arrhythmias. Circ Cardiovasc Imaging. 2012;5:12-20. https://doi.org/10.1161/CIRCIIMAGING.111.966085

64. Gutman SJ, Costello BT, Papapostolou S, Voskoboinik A, Iles L, Ja J, et al. Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar. Eur Heart J. 2019;40:542-50. https://doi.org/10.1093/eurheartj/ehy437

65. Fallavollita JA, Heavey BM, Luisi AJ, Michalek SM, Baldwa S, Mashtare TL, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63:141-9. https://doi.org/10.1016/j.jacc.2013.07.096

66. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882-90. https://doi.org/10.1056/NEJM199912163412503

67. Brembilla-Perrot B, Suty-Selton C, Beurrier D, Houriez P, Nippert M, Terrier de la Chaise A, et al. Differences in mechanisms and outcomes of syncope in patients with coronary disease or idio-pathic left ventricular dysfunction as assessed by electrophysiologic testing. J Am Coll Cardiol. 2004;44:594-601. https://doi.org/10.1016/j.jacc.2004.03.075

68. Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N Engl J Med. 2019;381:739-48. https://doi.org/10.1056/NEJMoa1807365

69. Olshansky B, Hahn EA, Hartz VL, Prater SP, Mason JW. Clinical significance of syncope in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. The ESVEM Investigators. Am Heart J. 1999;137:878-86. https://doi.org/10.1016/S0002-8703(99)70412-6

70. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793-867. https://doi.org/10.1093/eurheartj/ehv316

71. Al-Khatib SM, Stevenson WG, Ackerman MJ, Gillis AM, Bryant WJ, Hlatky MA, et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15:e190-e252.

72. Gann D, Tolentino A, Samet P. Electrophysiologic evaluation of elderly patients with sinus bradycardia: a long-term follow-up study. Ann Intern Med. 1979;90:24-9. https://doi.org/10.7326/0003-4819-90-1-24
73. Buxton AE, Fisher JD, Josephson ME, Lee KL, Pryor DB, Prystowsky EN, et al. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis. 1993;36:215-26. https://doi.org/10.1016/0033-0620(93)90015-6

74. Hilfiker G, Schoenenberger AW, Erne P, Kobza R. Utility of electrophysiological studies to predict arrhythmic events. World. J Cardiol. 2015;7:344-50. https://doi.org/10.4330/wjc.v7.i6.344

75. Mankbadi M, Hassan S, McGee M, Jan B, Mangal S, Altier J, et al. Brugada syndrome: the role of risk stratification in selecting patients for implantable cardioverter-defibrillator placement. Cureus. 2018;10:e2799. https://doi.org/10.7759/cureus.2799

76. Brugada J, Campuzano O, Arbelo E, Sarquella-Brugada G, Brugada R. Present status of Brugada syndrome: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:1046-59. https://doi.org/10.1016/j.jacc.2018.06.037

77. Sroubek J, Probst V, Mazzanti A, Delise P, Hevia JC, Ohkubo K, et al. Programmed ventricular stimulation for risk stratification in the Brugada syndrome: a pooled analysis. Circulation. 2016;133:622-30. https://doi.org/10.1161/CIRCULATIONO NAHA.115.017885

78. Solbiati M, Casazza G, Dipaola F, Barbic F, Caldato M, Montano N, et al. The diagnostic yield of implantable loop recorders in unexplained syncope: a systematic review and meta-analysis. Int J Cardiol. 2017;231:170-6. https://doi.org/10.1016/j.ijcard.2016.12.128

79. Ibrahim OA, Drew D, Hayes CJ, McIntyre W, Seifer CM, Hopman W, et al. Implantable loop recorders in the real world: a study of two Canadian centers. J Interv Card Electrophysiology. 2017;50:179-85. https://doi.org/10.1007/s10840-017-0294-y

80. Sanna T, Diener H-C, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478-86. https://doi.org/10.1056/NEJMoa1313600

81. Edvardsson N, Frykman V, van Mechelen R, Mitro P, Mohii-Oskarsson A, Pasquie JL, et al.;PICTURE Study Investigators. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. Europace. 2011;13:262-9. https://doi.org/10.1093/europace/euq418

82. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al.; ESC Scientific Document Group. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39:1883-948. https://doi.org/10.5603/KP.2018.0161

83. Shen WK, Sheldon RS, Benditt DG, Cohen MI, Forman DE, Goldberger ZD, et al. 2017 ACC/AHA/HRS Guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017;136:e60-e122. https://doi.org/10.1161/CIR.0000000000000499]

84. Roberts PR, Zachariah D, Morgan JM, Yue AM, Greenwood EF, Phillips PC, et al. Monitoring of arrhythmia and sudden death in a hemodialysis population: the CRASH-ILR Study. PLoS ONE. 2017;12:e0188713. https://doi.org/10.1371/journal.pone.0188713

85. Cheung CC, Krahn AD, Andrade JG. The emerging role of wearable technologies in detection of arrhythmia. Can J Cardiol. 2018;34:1083-7. https://doi.org/10.1016/j.cjca.2018.05.003

86. Bumgarner JM, Lambert CT, Hussein AA, Cantillon DJ, Baranowski B, Wolski K, et al. Smartwatch algorithm for automated detection of atrial fibrillation. J Am Coll Cardiol. 2018;71:2381-8. https://doi.org/10.1016/j.jacc.2018.03.003

87. Liu S. Number of Connected Wearable Devices Worldwide from 2016 to 2022. 2019. [cited 2020 Feb 1]. https://www.statista.com/statistics/487291/global-connected-wearable-devices/

88. Valiaho E-S, Kuoppa P, Lipponen JA, Martikainen TJ, Janti H, Rissanen TT, et al. Wrist band photoplethysmography in detection of individual pulses in atrial fibrillation and algorithm-based detection of atrial fibrillation. Europace. 2019;21:1031-8. https://doi.org/10.1093/europace/euz060

89. Brasier N, Raichle CJ, Dörr M, Becke A, Nohturffft V, Weber S, et al. Detection of atrial fibrillation with a smartphone camera: first prospective, international, two-centre, clinical validation study (DETECT AF PRO). Europace. 2019;21:41-7. https://doi.org/10.1093/europace/euy176

90. Verbrugge FH, Proesmans T, Vijgen J, Mullens W, Rivero-Ayerza M, Van Herendael H, et al. Atrial fibrillation screening with photo-plethysmography through a smartphone camera. Europace. 2019;21:1167-75. https://doi.org/10.1093/europace/euz119

91. Gillinov S, Etiwy M, Wang R, Blackburn G, Phelan D, Am G, et al. Variable accuracy of wearable heart rate monitors during aerobic exercise. Med Sci Sports Exerc. 2017;49:1697-703. https://doi.org/10.1249/MSS.0000000000001284

92. Wang R, Blackburn G, Desai M, Phelan D, Gillinov L, Houghtaling P, et al. Accuracy of wrist-worn heart rate monitors. JAMA Cardiol. 2017;2:104-6. https://doi.org/10.1001/jamacardio.2016.3340

93. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381:1909-17. https://doi.org/10.1056/NEJMoa1901183

94. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, et al. Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol. 2019;74:2365-75. https://doi.org/10.1016/j.jacc.2019.08.019

95. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13:1077-109. https://doi.org/10.1093/europace/eur245

96. Haugaa KH, Dan GA, Iliodromitis K, Lenarczyk R, Marinskis G, Osca J, et al. Management of patients with ventricular arrhythmias and prevention of sudden cardiac death-translating guidelines into practice: results of the European Heart Rhythm Association survey. Europace: european pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the. Eur Soc Cardiol. 2018;20:f249-f253. https://doi.org/10.1093/europace/euy112

97. Anastasakis A, Papatheodorou E, Ritsatos K, Protonotarios N, Rentoumi V, Gatzoulis K, et al. Sudden unexplained death in the young: epidemiology, aetiology and value of the clinically guided genetic screening. Europace. 2018;20:472-80. https://doi.org/10.1093/europace/euw362

98. Pontecorboli G, Figueras I, Carlosena A, Benito E, Prat-Gonzales S, Padeletti L, et al. Use of delayed-enhancement magnetic resonance imaging for fibrosis detection in the atria: a review. Europace. 2017;19:180-9.

99. Halliday BP, Cleland JGF, Goldberger JJ, Prasad SK. Personalizing risk stratification for sudden death in dilated cardiomyopathy: the past, present, and future. Circulation. 2017;136:215-31. https://doi.org/10.1161/CIRCULATIONAHA.116.027134

100. Margulescu AD, Nunez-Garcia M, Alarcon F, Benito EM, Enomoto N, Cozzari J, et al. Reproducibility and accuracy of late gadolinium enhancement cardiac magnetic resonance measurements for the detection of left atrial fibrosis in patients undergoing atrial fibrillation ablation procedures. Europace. 2019;21:724-31. https://doi.org/10.1093/europace/euy314

101. Goetze JP, Mogelvang R, Maage L, Scharling H, Schnohr P, Sogaard P, et al. Plasma pro-B-type natriuretic peptide in the general
population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J. 2006;27:3004-10. https://doi.org/10.1093/eurheartj/ehl406

102. Darkner S, Goetze JP, Chen X, Henningsen K, Pehrson S, Svendsen JH. Natriuretic propeptides as markers of atrial fibrillation burden and recurrence (from the AMIO-CAT Trial). Am J Cardiol. 2017;120:1309-15. https://doi.org/10.1016/j.amjca rd.2017.07.018

103. Sinner MF, Stepas KA, Moser CB, Krijthje BP, Aspelund T, Sotoodehnia N, et al. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace. 2014;16:1426-33. https://doi.org/10.1093/europace/euu175

104. Kemp Gudmundsdottir K, Fredriksson T, Svennberg E, Al-Khalili F, Friberg L, Frykman V, et al. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. Europace. 2020;22:24-32.

105. Segehri Shamloo A, Bollmann A, Dagres N, Hindricks G, Arya A. Natriuretic peptides: biomarkers for atrial fibrillation management. Clin Res Cardiol. 2020. https://doi.org/10.1007/s0039 2-020-01608-x. [Epub ahead of print].

106. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005;26:2083-92. https://doi.org/10.1093/eurheartj/ehi350

107. Nyrnes A, Njolstad I, Mathiesen EB, Wilsgaard T, Hansen JB, Skjelbakken T, et al. Inflammatory biomarkers as risk factors for future atrial fibrillation. An eleven-year follow-up of 6315 men and women: the Tromso study. Gend Med. 2012;9:536-47. e2. https:// doi.org/10.1016/j.genm.2012.09.001

108. Henningsen KM, Therkelsen SK, Johansen JS, Bruunsgaard H, Svendsen JH. Plasma YKL-40, a new biomarker for atrial fibrillation? Europace. 2009;11:1032-6.

109. Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin Electrophysiol. 2017;3:425-35. https://doi.org/10.1016/j.jacep.2017.03.002

110. Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, Nakamura K, et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels. 2005;20:45-9. https://doi.org/10.1007/s0038 0-004-0800-x

111. Henningsen KM, Nilsson B, Bruunsgaard H, Chen X, Pedersen BK, Svendsen JH. Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Scand Cardiovasc J. 2009;43:285-91. https://doi. org/10.1080/14017430802653676

112. Henningsen KM, Therkelsen SK, Bruunsgaard H, Krabbe KS, Pedersen BK, Svendsen JH. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest. 2009;69:425-32. https:// doi.org/10.1080/00365510802676848

113. Aronson D, Boulos M, Suleiman A, Bidoosi S, Agmon Y, Kapeliovich M, et al. Relation of C-reactive protein and new-onset atrial fibrillation in patients with acute myocardial infarction. Am J Cardiol. 2007;100:753-7. https://doi.org/10.1016/j.amjca rd.2007.04.014

114. Canpolat U, Aytemir K, Hazirolan T, Ozer N, Oto A. Serum YKL-40 as a marker of left atrial fibrosis assessed by delayed enhancement MRI in lone atrial fibrillation. Pacing Clin Electrophysiol. 2015;38:1386-95. https://doi.org/10.1111/pace.12729

115. Henningsen KM, Nilsson B, Johansen JS, Chen X, Pehrson S, Svendsen JH. Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation. Inflamm Res. 2010;59:463-9. https://doi.org/10.1007/s00011-009-0146-z

116. Marott SCW, Benn M, Johansen JS, Jensen GB, Tybjaerg-Hansen A, Nordestgaard BG. YKL-40 levels and atrial fibrillation in the

general population. Int J Cardiol. 2013;167(4):1354-9. https://doi. org/10.1016/j.ijcard.2012.04.006

117. Van Wagoner DR, Piccini JP, Albert CM, Anderson ME, Benjamin EJ, Brundel B, et al. Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. Heart Rhythm. 2015;12(1):e5-e29. https://doi.org/10.1016/j. hrthm.2014.11.011

118. Fenger-Gron M, Overvad K, Tjonneland A, Frost L. Lean body mass is the predominant anthropometric risk factor for atrial fibrillation. J Am Coll Cardiol. 2017;69:2488-97. https://doi.org/10.1016/j. jacc.2017.03.558

119. Sandhu RK, Conen D, Tedrow UB, Fitzgerald KC, Pradhan AD, Ridker PM, et al. Predisposing factors associated with development of persistent compared with paroxysmal atrial fibrillation. J Am Heart Assoc. 2014;3(3):e000916. https://doi.org/10.1161/ JAHA.114.000916

120. Frost L, Benjamin EJ, Fenger-Gron M, Pedersen A, Tjønneland A, Overvad K. Body fat, body fat distribution, lean body mass and atrial fibrillation and flutter. A Danish cohort study. Obesity. 2014;22(6):1546-52. https://doi.org/10.1002/oby.20706

121. Zhuang J, Lu Y, Tang K, Peng W, Xu Y. Influence of body mass index on recurrence and quality of life in atrial fibrillation patients after catheter ablation: a meta-analysis and systematic review. Clin Cardiol. 2013;36:269-75. https://doi.org/10.1002/clc.22108

122. Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M, et al. Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation. Heart Rhythm. 2013;10(1):90-100. https://doi.org/10.1016/j.hrthm.2012.08.043

123. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace. 2013;15(10):1389-406.

124. Schwartz PJ, Spazzolini C, Crotti L, Bathen J, Amlie JP, Timothy K, et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation. 2006;113:783-90. https://doi.org/10.1161/CIRCULATIONAHA.105.592899

125. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119:19-31. https://doi.org/10.1016/j.cell.2004.09.011

126. Barsheshet A, Goldenberg I, O-Uchi J, Moss AJ, Jons C, Shimizu W, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to beta-blocker therapy in type 1 long-QT syndrome. Circulation. 2012;125:1988-96. https://doi.org/10.1161/ CIRCULATIONAHA.111.048041

127. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc D, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children: a 7-year follow up of 21 patients. Circulation. 1995;91:1512-9. https://doi.org/10.1161/01.CIR.91.5.1512

128. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003;89:66-70. https://doi.org/10.1136/heart.89.1.66

129. van der Werf C, Nederend I, Hofman N, van Geloven N, Ebink C, Frohn-Mulder IME, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol. 2012;5:748-56. https://doi. org/10.1161/CIRCEP.112.970517

130. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, et al. An international compendium of mutations in the
SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010;7:33-46. https://doi.org/10.1016/j.hrthm.2009.09.069

131. Liu M, Yang KC, Dudley SC Jr. Cardiac sodium channel mutations: why so many phenotypes? Nat Rev Cardiol. 2014;11:607-15. https://doi.org/10.1038/nrcardio.2014.85

132. Phenotype ELL. genotype, and cellular physiology: need for clarity in characterization. Heart Rhythm. 2012;9:1993-4. https://doi.org/10.1016/j.hrthm.2012.08.033

133. Weng L-C, Lunetta KL, Müller-Nurasyid M, Smith AV, Thériault S, Weeke PE, et al. Genetic interactions with age, sex, body mass index, and hypertension in relation to atrial fibrillation: the AFGen consortium. Sci Rep. 2017;7:11303. https://doi.org/10.1038/s41598-017-09396-7

134. Weng L-C, Preis SR, Hulme OL, Larson MG, Choi SH, Wang B, et al. Genetic predisposition, clinical risk factor burden, and lifetime risk of atrial fibrillation. Circulation. 2018;137:1027-38. https://doi.org/10.1161/CIRCULATIONAHA.117.031431

135. Ahlberg G, Refsgaard L, Lundegaard PR, Andreasen L, Ranthe MF, Linscheid N, et al. Rare truncating variants in the sarcomeric protein titin associate with familial and early-onset atrial fibrillation. Nat Commun. 2018;9:4316. https://doi.org/10.1038/s41467-018-06618-y

136. Roselli C, Chaffin MD, Weng LC, Aeschbacher S, Ahlberg G, Albert CM, et al. Multi-ethnic genome-wide association study for atrial fibrillation. Nat Genet. 2018;50:1225-33. https://doi.org/10.1038/s41588-018-0133-9

137. Hannun AY, Rajpurkar P, Haghpanahi M, Tison GH, Bourn C, Turakhia MP, et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25:65-9. https://doi.org/10.1038/s41591-018-0268-3

138. Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet. 2019;394(10201):861-7.

139. Ebrahimzadeh E, Kalantari M, Joulani M, Shahraki RS, Fayaz F, Ahmadi F. Prediction of paroxysmal Atrial Fibrillation: a machine learning based approach using combined feature vector and mixture of expert classification on HRV signal. Comput Methods Programs Biomed. 2018;165:53-67. https://doi.org/10.1016/j.cmpb.2018.07.014

140. Attia ZI, Kapa S, Lopez-Jimenez F, McKie PM, Ladewig DJ, Satam G, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med. 2019;25:70-4. https://doi.org/10.1038/s41591-018-0240-2

141. Motwani M, Dey D, Berman DS, Germano G, Achenbach S, Al-Mallah MH, et al. Machine learning for prediction of all-cause mortality in patients with suspected coronary artery disease: a 5-year multicentre prospective registry analysis. Eur Heart J. 2017;38:500-7. https://doi.org/10.1093/eurheartj/ehw188

142. Narula S, Shameer K, Salem Omar AM, Dudley JT, Sengupta PP. Machine-learning algorithms to automate morphological and functional assessments in 2D echocardiography. J Am Coll Cardiol. 2016;68:2287-95. https://doi.org/10.1016/j.jacc.2016.08.062

143. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015;386:154-62. https://doi.org/10.1016/S0140-6736(14)61774-8

144. Andrade JG, Deyell MW, Lee AYK, Macle L. Sex differences in atrial fibrillation. Can J Cardiol. 2018;34:429-36. https://doi.org/10.1016/j.cjca.2017.11.022

145. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120:1501-17. https://doi.org/10.1161/CIRCRESAHA.117.309732

146. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-47. https://doi.org/10.1161/CIRCULATIONAHA.113.005119

147. Stefansdottir H, Aspelund T, Gudnason V, Arnar DO. Arnar DO. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace. 2011;13:1110-7. https://doi.org/10.1093/europace/eur132

148. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-25. https://doi.org/10.1161/CIRCULATIONAHA.105.595140

149. Kloosterman M, Crijns HJGM, Mulder BA, Groenveld HF, Van Veldhuisen DJ, Rienstra M, et al. Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study. Europace. 2019. https://doi.org/10.1093/europace/euz300. [Epub ahead of print].

150. Cheng X, Hu Q, Gao L, Liu J, Qin S, Zhang D. Sex-related differences in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace. 2019;21:1509-18. https://doi.org/10.1093/europace/euz179

151. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114:1453-68. https://doi.org/10.1161/CIRCRESAHA.114.303211

152. Murphy NF, Simpson CR, Jhund PS, Stewart S, Kirkpatrick M, Chalmers J, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart. 2007;93:606-12. https://doi.org/10.1136/hrt.2006.107573

153. Rodriguez CJ, Soliman EZ, Alonso A, Swett K, Okin PM, Goff DC Jr, et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol. 2015;25(2):71-6. e1. https://doi.org/10.1016/j.annepidem.2014.11.024

154. Naderi S, Wang Y, Miller AL, Rodriguez F, Chung MK, Radford MJ, et al. The impact of age on the epidemiology of atrial fibrillation hospitalizations. Am J Med. 2014;127:158.e1-7.

155. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-53. https://doi.org/10.1093/eurheartj/ehi825

156. Chao T-F, Liu C-J, Tuan T-C, Chen T-J, Hsieh M-H, Lip GYH, et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan nationwide AF cohort study. Chest. 2018;153:453-66. https://doi.org/10.1016/j.chest.2017.10.001

157. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016;13:321-32. https://doi.org/10.1038/nrcardio.2016.45

158. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB. Copenhagen City Heart Study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol. 2004;94:889-94. https://doi.org/10.1016/j.amjcard.2004.06.023

159. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, et al. Mortality trends in patients diagnosed with first atrial
fibrillation: a 21-year community-based study. J Am Coll Cardiol.
2007;49:986-92. https://doi.org/10.1016/j.jacc.2006.10.062

160. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2n-9n. https://doi.org/10.1016/S0002-9149(98)00583-9

161. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices. Eur Heart J. 2014;35:508-16. https://doi.org/10.1093/eurheartj/eht491

162. Shaikh AY, Maan A, Khan UA, Aurigemma GP, Hill JC, Kane JL, et al. Speckle echocardiographic left atrial strain and stiffness index as predictors of maintenance of sinus rhythm after cardioversion for atrial fibrillation: a prospective study. Cardiovasc Ultrasound. 2012;10:48. https://doi.org/10.1186/1476-7120-10-48

163. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014;311:498-506. https://doi.org/10.1001/jama.2014.3

164. Skanes AC, Tang A. Atrial fibrillation and heart failure: untangling a modern Gordian knot. Can J Cardiol. 2018;34:1437-48. https://doi.org/10.1016/j.cjca.2018.07.483

165. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;56:1712-9. https://doi.org/10.1016/j.jacc.2010.05.049

166. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012;44:670-5. https://doi.org/10.1038/ng.2261

167. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133:484-92. https://doi.org/10.1161/CIRCULATIONAHA.115.018614

168. Buza V, Rajagopalan B, Curtis AB. Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies. Circ Arrhythm Electrophysiol. 2017;10. https://doi.org/10.1161/CIRCEP.117.005443

169. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodynam J, Kara T, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49:565-71. https://doi.org/10.1016/j.jacc.2006.08.060

170. Djoussé L, Levy D, Benjamin EJ, Blease SJ, Russ A, Larson MG, et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol. 2004;93:710-3. https://doi.org/10.1016/j.amjcard.2003.12.004

171. Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ. 2012;345:e7895. https://doi.org/10.1136/bmj.e7895

172. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol. 1990;15:1279-85. https://doi.org/10.1016/S0735-1097(10)80014-2

173. Go AS, Hylek EM, Phillips KA, Chang YuChiao, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-5. https://doi.org/10.1001/jama.285.18.2370

174. Magnani JW, Zhu L, Lopez F, Pencina MJ, Agarwal SK, Soliman EZ, et al. P-wave indices and atrial fibrillation: cross-cohort assessments from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2015;169:53-61. e1. https://doi.org/10.1016/j.ahj.2014.10.009

175. Fox CS, Parise H, D'Agostino RB Sr, Lloyd-Jones DM, Vasan RS, Wang TJ, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 2004;291:2851-5. https://doi.org/10.1001/jama.291.23.2851

176. Allan V, Honarbakhsh S, Casas J-P, Wallace J, Hunter R, Schilling R, et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synthesis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017;117:837-50. https://doi.org/10.1160/TH16-11-0825

177. Li YG, Pastori D, Farcomeni A, Yang PS, Jang E, Joung B, et al. A simple clinical risk score (C2HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects. Chest. 2019;155(3):510-8. https://doi.org/10.1016/j.chest.2018.09.011

178. Yan-Guang L, Bisson A, Bodin A, et al. The C2HEST score and the prediction of incident atrial fibrillation in post-stroke subjects: a French nationwide study. J Am Heart Assoc. 2019;8(13):e012546.

179. Hu WS, Hsieh MH, Lin CL. A novel atrial fibrillation prediction model for Chinese subjects: a nationwide cohort investigation of 682 237 study participants with random forest model. Europace. 2019;21:1307-12. https://doi.org/10.1093/europace/euz036

180. Li Y, Pastori D, Guo Y, Wang Y, Lip G. Risk factors for new-onset atrial fibrillation: a focus on Asian populations. Int J Cardiol. 2018;261:92-8. https://doi.org/10.1016/j.ijcard.2018.02.051

181. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess. 2005;9:iii-iv, ix-x, 1-74. https://doi.org/10.3310/hta9400

182. Long MJ, Jiang CQ, Lam TH, Xu L, Zhang WS, Lin JM, et al. Atrial fibrillation and obesity among older Chinese: the Guangzhou Biobank Cohort Study. Int J Cardiol. 2011;148:48-52. https://doi.org/10.1016/j.ijcard.2009.10.022

183. Boriani G, Laroche C, Diemberger I, Fantecchi E, Meeder J, Kurpesa M, et al. Overweight and obesity in patients with atrial fibrillation: sex differences in 1-year outcomes in the EORP-AF General Pilot Registry. J Cardiovasc Electrophysiol. 2018;29:566-72. https://doi.org/10.1111/jce.13428

184. Proietti M, Guiducci E, Cheli P, Lip GY. Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials. Stroke. 2017;48:857-66. https://doi.org/10.1161/STROK EHA.116.015984

185. Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, et al. PREVEntion and regReSSive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018;20:1929-35. https://doi.org/10.1093/europace/euy117

186. Kim D, Yang P-S, Kim T-H, Jang E, Shin H, Kim HY, et al. Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol. 2018;72:1233-45. https://doi.org/10.1016/j.jacc.2018.05.076

187. Kim T-H, Yang P-S, Yu HT, Jang E, Shin H, Kim HY, et al. Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population. Eur Heart J. 2019;40(10):809-19.
188. Overvad TF, Skjøth F, Lip GYH, Lane DA, Albertsen IE, Rasmussen LH, et al. Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study. Stroke. 2015;46:2168-74. https://doi.org/10.1161/STROK EAHA.115.009371

189. Fangel MV, Nielsen PB, Larsen TB, Christensen BO, Overvad TF, Lip GYH, et al. versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: a Danish nationwide cohort study. Int J Cardiol. 2018;268:137-42. https://doi.org/10.1016/j.ijcard.2018.05.037

190. Lip GY, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2015;147:1103-10. https://doi.org/10.1378/chest.14.2096

191. Ashburner JM, Go AS, Chang Y, Fang MC, Fredman L, Applebaum KM, et al. Effect of diabetes and glycemic control on ischemic stroke risk in AF patients: ATRIA study. J Am Coll Cardiol. 2016;67:239-47. https://doi.org/10.1016/j.jacc.2015.10.080

192. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J. 2012;76:2289-304. https://doi.org/10.1253/circj.CJ-12-1036

193. Lip GYH, Collet JP, de Caterina R, Fauchier L, Lane DA, Larsen TB, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: executive summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Thromb Haemost. 2017;117:2215-36. https://doi.org/10.1160/TH-17-10-0709

194. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail. 2012;14:295-301. https://doi.org/10.1093/eurjhf/hfs005

195. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB. Lip GY. Assessment of the CHA2DS2VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314:1030-8. https://doi.org/10.1001/jama.2015.10725

196. Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, et al. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med. 2016;374:1911-21. https://doi.org/10.1056/NEJMoa1602002

197. Mathew J. Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004;291:1720-9. https://doi.org/10.1001/jama.291.14.1720

198. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, et al. Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. Circulation. 1996;94:390-7. https://doi.org/10.1161/01.CIR.94.3.390

199. Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality. Eur J Cardio-Thorac Surg. 2010;37:1353-9. https://doi.org/10.1016/j.ejcts.2009.12.033

200. Dobrev D, Aguilar M, Heijman J, Guichard J-B, Nattel S. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nat Rev Cardiol. 2019;1. https://doi.org/10.1038/s41569-019-0166-5

201. Echahidi N, Pibarot P, O'Hara G, Mechanisms MP. prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008;51:793-801. https://doi.org/10.1016/j.jacc.2007.10.043

202. Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah AS, Habib RH. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation. 2005;112:3247-55. https://doi.org/10.1161/CIRCULATIONAHA.105.553743

203. Lowres N, Mulcahy G, Jin K, Gallagher R, Neubeck L, Freedman B. Incidence of postoperative atrial fibrillation recurrence in patients discharged in sinus rhythm after cardiac surgery: a systematic review and meta-analysis. Interact Cardiovasc Thoracic Surg. 2018;26:504-11. https://doi.org/10.1093/icvts/ivx348

204. National Collaborating Centre for Chronic Conditions (UK). Stroke: National Clinical Guideline for Diagnosis and Initial Management of Acute Stroke and Transient Ischaemic Attack (TIA). London: Royal College of Physicians; 2008.

205. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947. https://doi.org/10.1161/STR.0b103e318284056a

206. Steinberg JS, Varma N, Cygankiewicz I, Aziz P, Balsam P, Baranchuk A, et al. ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm. 2017;14:e55-e96 https://doi.org/10.1016/j.hrthm.2017.03.038

207. Sposato LA, Cipriano LE, Saposnik G, Vargas ER, Riccio PM, Hachinski V. Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14:377-87. https://doi.org/10.1016/S1474-4422(15)70027-X

208. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41. https://doi.org/10.1161/01.STR.24.1.35

209. Dussault C, Toeg H, Nathan M, Wang ZJ, Roux J-F, Secemsky E. Electrocardiographic monitoring for detecting atrial fibrillation after ischemic stroke or transient ischemic attack: systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2015;8:263-9. https://doi.org/10.1161/CIRCEP.114.002521

210. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467-77. https://doi.org/10.1056/NEJMoa1311376

211. Li YG, Bisson A, Bodin A, Herbert J, Grammatico-Guillon L, Joung B, et al. C2 HEST Score and prediction of incident atrial fibrillation in poststroke patients: a French Nationwide Study. J Am Heart Assoc. 2019;8:e012546. https://doi.org/10.1161/JAHA.119.012546

212. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. Europace. 2009;11:1156-9. https://doi.org/10.1093/europace/eup197

213. Heidbuchel H, Anne W, Willems R, Adriaenssens B, Van de Werf F, Ector H. Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. Int J Cardiol. 2006;107:67-72. https://doi.org/10.1016/j.ijcard.2005.02.043

214. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol. 2009;103:1572-7. https://doi.org/10.1016/j.amjca rd.2009.01.374

215. Hoogsteen J, Schep G, Van Hemel NM, Van Der Wall EE. Paroxysmal atrial fibrillation in male endurance athletes. A 9-year
follow up. Europace. 2004;6:222-8. https://doi.org/10.1016/j.eupc.2004.01.004

216. Swanson DR. Atrial fibrillation in athletes: implicit literature-based connections suggest that overtraining and subsequent inflammation may be a contributory mechanism. Med Hypotheses. 2006;66:1085-92. https://doi.org/10.1016/j.mehy.2006.01.006

217. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation. 2002;105:2753-9. https://doi.org/10.1161/01.CIR.0000018443.44005.D8

218. McGann C, Akoum N, Patel A, Kholmovski E, Revelo P, Damal K, et al. Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI. Circ Arrhythm Electrophysiol. 2014;7:23-30. https://doi.org/10.1161/CIRCEP.113.000689

219. Ho SY, Sanchez-Quintana D, Cabrera JA, Anderson RH. Anatomy of the left atrium: implications for radiofrequency ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 1999;10:1525-33. https://doi.org/10.1111/j.1540-8167.1999.tb00211.x

220. Qureshi WT, Alirhayim Z, Blaha MJ, Juraschek SP, Keteyian SJ, Brawner CA, et al. Cardiorespiratory Fitness and risk of incident atrial fibrillation: results from the Henry Ford Exercise Testing (FIT) project. Circulation. 2015;131:1827-34. https://doi.org/10.1161/CIRCULATIONAHA.114.014833

221. Allison MA, Jensky NE, Marshall SJ, Bertoni AG, Cushman M. Sedentary behavior and adiposity-associated inflammation: the Multi-Ethnic Study of Atherosclerosis. Am J Preventive Med. 2012;42:8-13. https://doi.org/10.1016/j.amepre.2011.09.023

222. Malvo V, Nes BM, Amundsen BH, Tjonna A-E, Stoylen A, Rossvoll O, et al. Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. Circulation. 2016;133:466-73. https://doi.org/10.1161/CIRCULATIONAHA.115.018220

223. Pelliccia A, Culasso F, Di Paolo FM, Maron BJ. Physiologic left ventricular cavity dilatation in elite athletes. Ann Intern Med. 1999;130:23-31. https://doi.org/10.7326/0003-4819-130-1-199901050-00005

224. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886-91. https://doi.org/10.1161/hc4901.101760

225. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit. 2003;9:Ra225-9.

226. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol. 2005;95:764-7. https://doi.org/10.1016/j.amjcard.2004.11.032

227. Mont L, Elosua R, Brugada J. Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter. Europace. 2009;11:11-7.

228. Mohlenkamp S, Lehmann N, Breuckmann F, Brocker-Preuss M, Nassenstein K, Halle M, et al.; on behalf of the Marathon Study Investigators and the Heinz Nixdorf Recall Study Investigators. Running: the risk of coronary events: prevalence and prognostic relevance of coronary atherosclerosis in marathon runners. Eur Heart J. 2008;29:1903-10. https://doi.org/10.1093/eurheartj/ehn163

229. Benito B, Gay-Jordi G, Serrano-Mollar A, Guasch E, Shi Y, Tardif J-C, et al. Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation. 2011;123:13-22. https://doi.org/10.1161/CIRCULATIONAHA.110.938282

230. Boraita A, Santos-Lozano A, Heras ME, Gonzalez-Amigo F, Lopez-Ortiz S, Villacastin JP, et al. Incidence of atrial fibrillation in elite athletes. JAMA Cardiol. 2018;3:1200. https://doi.org/10.1001/jamacardio.2018.3482

231. Cuspidi C, Tadic M, Sala C, Gherbesi E, Grassi G, Mancia G. Left atrial function in elite athletes: a meta-analysis of two-dimensional speckle tracking echocardiographic studies. Clin Cardiol. 2019;42:579-87. https://doi.org/10.1002/clc.23180

232. Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19:1319-21. https://doi.org/10.1111/j.1540-8167.2008.01211.x

233. Miyake CY, Webster G, Czosek RJ, Kantoch MJ, Dubin AM, Avasarala K, et al. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate. Circ Arrhythm Electrophysiol. 2013;6:579-87. https://doi.org/10.1161/CIRCEP.113.000170

234. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm. 2005;2:429-40. https://doi.org/10.1016/j.hrthm.2005.01.005

235. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20:1391-6. https://doi.org/10.1016/0735-1097(92)90253-J

236. Eckardt L, Kirchhof P, Loh P, Schulze-bahr E, Johna R, Wichter T, et al. Brugada syndrome and supraventricular tachyarrhythmias: a novel association? J Cardiovasc Electrophysiol. 2001;12:680-5. https://doi.org/10.1046/j.1540-8167.2001.00680.x

237. Morita H, Kusano-Fukushima K, Nagase S, Fujimoto Y, Hisamatsu K, Fujio H, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol. 2002;40(8):1437-44. https://doi.org/10.1016/S0735-1097(02)02167-8

238. Francis J, Antzelevitch C. Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol. 2008;51:1149-53. https://doi.org/10.1016/j.jacc.2007.10.062

239. Bordachar P, Reuter S, Garrigue S, Cai X, Hocini M, Jais P, et al. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J. 2004;25:879-84. https://doi.org/10.1161/CIRCULATIONAHA.106.628537

240. Bigi MA, Aslani A, Shahrzad S. Clinical predictors of atrial fibrillation in Brugada syndrome. Europace. 2007;9:947-50.

241. Sacher Frédéric, Probst V, lesaka Y, Jacon P, Laborderie J, Mizon-Gérard Frédérique, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation. 2006;114:2317-24. https://doi.org/10.1161/CIRCULATIONAHA.106.628537

242. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm. 2008;5:704-9. https://doi.org/10.1016/j.hrthm.2008.02.007

243. Knoche JW, Orland KM, January CT, Maginot KR. Atrial fibrillation and long QT syndrome presenting in a 12-year-old girl. Case Rep Pediatr. 2012;2012:124838. https://doi.org/10.1155/2012/124838

244. Sankaranarayanan R, Kirkwood G, Dibb K, Garratt CJ. Comparison of atrial fibrillation in the young versus that in the elderly: a review. Cardiol Res Pract. 2013;2013:1-16. https://doi.org/10.1155/2013/976976

245. Chen YH, Xu SJ, Bendahhou S, Wang XL, Wang Y, Xu WY, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science. 2003;299:251-4. https://doi.org/10.1126/science.1077771

246. Lieve KV, Verkerk AO, Podliesna S, van der Werf C, Tanck MW, Hofman N, et al. Gain-of-function mutation in SCN5A causes ventricular arrhythmias and early onset atrial fibrillation.
Int J Cardiol. 2017;236:187-93. https://doi.org/10.1016/j.ijcard.2017.01.113

247. Kirchhof P, Eckardt L, Franz MR, Monnig G, Loh P, Wedekind H, et al. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol. 2003;14:1027-33. https://doi.org/10.1046/j.1540-8167.2003.03165.x

248. Maruyama M, Joung B, Tang L, Shinohara T, On Y-K, Han S, et al. Diastolic intracellular calcium-membrane voltage coupling gain and postshock arrhythmias: role of Purkinje fibers and triggered activity. Circ Res. 2010;106:399-408. https://doi.org/10.1161/CIRCRESAHA.109.211292

249. Morotti S, McCulloch AD, Bers DM, Edwards AG, Grandi E. Atrial-selective targeting of arrhythmogenic phase-3 early afterdepolarizations in human myocytes. J Mol Cell Cardiol. 2016;96:63-71. https://doi.org/10.1016/j.yjmcc.2015.07.030

250. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 2004;109:30-5. https://doi.org/10.1161/01.CIR.0000109482.92774.3A

251. Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol. 2005;16:394-6. https://doi.org/10.1046/j.1540-8167.2005.40621.x

252. Priori SG, Pandit SV, Rivolta I, Berenfeld O, Ronchetti E, Dhamoon A, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res. 2005;96:800-7. https://doi.org/10.1161/01.RES.0000106210.76263.8c

253. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise T, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103:196-200. https://doi.org/10.1161/01.CIR.103.2.196

254. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff J-M, Da Costa A, Sebillon P, et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2002;91:1-6.

255. Marsman RF, Barc J, Beekman L, Alders M, Dooijes D, van den Wijngaard A, et al. A mutation in CALM1 encoding calmodulin in familial idiopathic ventricular fibrillation in childhood and adolescence. J Am Coll Cardiol. 2014;63:259-66. https://doi.org/10.1016/j.jacc.2013.07.091

256. Lieve KVV, Verhagen JMA, Wei J, Bos JM, van der Werf C, Roses i Noguer F, et al. Linking the heart and the brain: neurodevelopmental disorders in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2019;16:220-8. https://doi.org/10.1016/j.hrthm.2018.08.025

257. Lip GYH, Jensen M, Melgaard L, Skjoth F, Nielsen PB, Larsen TB. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study. Europace. 2019;21:33-40. https://doi.org/10.1093/europace/euy151

258. Dagres N, Chao TF, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, et al.;ESC Scientific Document Group. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Europace. 2018;20:1399-421. https://doi.org/10.1093/europace/euy046

259. Krawczyk M, Fridman S, Cheng Y, Fang J, Saposnik G, Sposato LA. Atrial fibrillation diagnosed after stroke and dementia risk: cohort study of first-ever ischaemic stroke patients aged 65 or older. Europace. 2019. https://doi.org/10.1093/europace/euz237. [Epub ahead of print].

260. Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015;14:926-44. https://doi.org/10.1016/S1474-4422(15)00153-2

261. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609-78. https://doi.org/10.1093/europace/euw295

262. Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ. 2013;346(may02 1):f2573. https://doi.org/10.1136/bmj.f2573

263. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2:e000250. https://doi.org/10.1161/JAHA.113.000250

264. Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37:1582-90. https://doi.org/10.1093/eurheartj/ehw054

265. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67. https://doi.org/10.7326/0003-4819-146-12-200706190-00007

266. Fauchier L, Clementy N, Bisson A, Ivanes F, Angoulvant D, Babuty D, et al. Should atrial fibrillation patients with only 1 nongender-related CHA₂DS₂-VASc risk factor be anticoagulated? Stroke. 2016;47:1831-6. https://doi.org/10.1161/STROK EAHA.116.013253

267. Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke and major bleeding risk in elderly patients aged >/=75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke. 2015;46:143-50. https://doi.org/10.1161/STROK EAHA.114.007199

268. Chao T-F, Lip GYH, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F, et al. Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities. Eur Heart J. 2019;40:1504-14. https://doi.org/10.1093/eurheartj/ehy837

269. Sepehri Shamloo A, Dagres N, Mussigbrodt A, Stauber A, Kircher S, Richter S, et al. Atrial fibrillation and cognitive impairment: new insights and future directions. Heart Lung Circ. 2020;29:69-85. https://doi.org/10.1016/j.hlc.2019.05.185

270. Schwarz N, Kuniss M, Nedelmann M, Kaps M, Bachmann G, Neumann T, et al. Neuropsychological decline after catheter ablation of atrial fibrillation. Heart Rhythm. 2010;7:1761-7. https://doi.org/10.1016/j.hrthm.2010.07.035

271. Saw J, Tzikas A, Shakir S, Gafoor S, Omran H, Nielsen-Kudsk JE, et al. Incidence and clinical impact of device-associated thrombus and peri-device leak following left atrial appendage closure with the Amplatzer Cardiac Plug. JACC Cardiovasc Interv. 2017;10:391-9. https://doi.org/10.1016/j.jcin.2016.11.029

272. Viles-Gonzalez JF, Kar S, Douglas P, Dukkipati S, Feldman T, Horton R, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol. 2012;59:923-9. https://doi.org/10.1016/j.jacc.2011.11.028
273. Dukkipati SR, Kar S, Holmes DR, Doshi SK, Swarup V, Gibson DN, et al. Device-related thrombus after left atrial appendage closure. Circulation. 2018;138:874-85. https://doi.org/10.1161/CIRCU LATIONAHA.118.035090

274. Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Abbey S, et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol. 2018;71:1528-36. https://doi.org/10.1016/j.jacc.2018.01.076

275. Saw J, Fahmy P, DeJong P, Lempereur M, Spencer R, Tsang M, et al. Cardiac CT angiography for device surveillance after endovascular left atrial appendage closure. Eur Heart J Cardiovasc Imaging. 2015;16:1198-206. https://doi.org/10.1093/ehjci/jev067

276. Berte B, Jost CA, Maurer D, Fäh-Gunz A, Pillois X, Naegeli B, et al. Long-term follow-up after left atrial appendage occlusion with comparison of transesophageal echocardiography vs. computed tomography to guide medical therapy and data about post-closure cardioversion. J Cardiovasc Electrophysiol. 2017;28:1140-50. https://doi.org/10.1111/jce.13289

277. Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JB Jr, et al. Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial fibrillation. J Thorac Cardiovasc Surg. 2005;130:797-802. https://doi.org/10.1016/j. jtcvs.2005.03.041

278. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace. 2017;2018(20):157-208. https:// doi.org/10.1093/europace/eux275

279. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. https://doi.org/10.1093/eurheartj/ehw210

280. Schellinger PD, Tsivgoulis G, Steiner T, Kohrmann M. Percutaneous left atrial appendage occlusion for the prevention of stroke in patients with atrial fibrillation: review and critical appraisal. J Stroke. 2018;20:281-91. https://doi.org/10.5853/jos.2018.02537

281. Sharma SP, Park P, Lakkireddy D. Left atrial appendages occlusion: current status and prospective. Korean Circ J. 2018;48:692-704. https://doi.org/10.4070/kcj.2018.0231

282. Caliskan E, Sahin A, Yilmaz M, Seifert B, Hinzpeter R, Alkadhi H, et al. Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. Europace. 2018;20:e105-e114. https://doi. org/10.1093/europace/eux211

283. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312:1988-98. https://doi.org/10.1001/jama.2014.15192

284. Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1-12. https://doi.org/10.1016/j. jacc.2014.04.029

285. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964-75. https://doi.org/10.1016/j.jacc.2017.10.021

286. Aryana A, Singh SK, Singh SM, Gearoid O'Neill P, Bowers MR, Allen SL, et al. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. Heart Rhythm 2015;12:1431-7. https://doi.org/10.1016/j. hrthm.2015.03.028

287. Mohanty S, Gianni C, Trivedi C, Gadiyaram V, Della Rocca DG, MacDonald B, et al. Risk of thromboembolic events after

percutaneous left atrial appendage ligation in patients with atrial fibrillation: long-term results from a multicenter study. Heart Rhythm. 2019. https://doi.org/10.1016/j.hrthm.2019.08.003

288. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015;36:3250-7. https://doi.org/10.1093/eurheartj/ehv513

289. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920-5. https://doi.org/10.1161/01. CIR.0000072767.89944.6E

290. Denham NC, Pearman CM, Caldwell JL, Madders GW, Eisner DA, Trafford AW, et al. Calcium in the pathophysiology of atrial fibrillation and heart failure. Front Physiol. 2018;9. https://doi. org/10.3389/fphys.2018.01380

291. Deedwania PC, Lardizabal JA. Atrial fibrillation in heart failure: a comprehensive review. Am J Med. 2010;123:198-204. https://doi. org/10.1016/j.amjmed.2009.06.033

292. Muller-Edenborn B, Minners J, Allgeier J, Burkhardt T, Lehrmann H, Ruile P, et al. Rapid improvement in left ventricular function after sinus rhythm restoration in patients with idiopathic cardiomyopathy and atrial fibrillation. Europace. 2019;21:871-8. https:// doi.org/10.1093/europace/euz013

293. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359-64. https://doi.org/10.1016/S0002 -9343(02)01236-6

294. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47:1997-2004. https://doi.org/10.1016/j. jacc.2006.01.060

295. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol. 2016;203:660-6. https://doi. org/10.1016/j.ijcard.2015.10.220

296. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al.;for the CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1261. https:// doi.org/10.1001/jama.2019.0693

297. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417-27. https://doi.org/10.1056/ NEJMoa1707855

298. Mathew JS, Marzec LN, Kennedy KF, Jones PG, Varosy PD, Masoudi FA, et al. Atrial fibrillation in heart failure US ambulatory cardiology practices and the potential for uptake of catheter ablation: an National Cardiovascular Data Registry (NCDR(R)) Research to Practice (R2P) Project. J Am Heart Assoc. 2017;6(8):1-11. e005273.

299. Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016;388:1161-9. https://doi.org/10.1016/S0140 -6736(16)30968-0

300. Fauchier L, Samson A, Chaize G, Gaudin AF, Vainchtock A, Bailly C, et al. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open. Heart. 2015;2:e000290. https://doi.org/10.1136/openh rt-2015-000290
301. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc. 2016;7:e00219. https://doi.org/10.1161/JAHA.118.008755

302. Turagam MK, Velagapudi P, Visotcky A, Szabo A, Kocheril AG. African Americans have the highest risk of in-hospital mortality with atrial fibrillation related hospitalizations among all racial/ethnic groups: a nationwide analysis. Int J Cardiol. 2012;158:165-6. https://doi.org/10.1016/j.ijcard.2012.04.090

303. Jacobs V, May HT, Bair TL, Crandall BG, Cutler M, Day JD, et al. The impact of risk score (CHADS2 versus CHA2DS2VASc) on long-term outcomes after atrial fibrillation ablation. Heart Rhythm. 2015;12:681-6. https://doi.org/10.1016/j.hrthm.2014.12.034

304. Fox KAA, Lucas JE, Pieper KS, Bassand J-P, Camm AJ, Fitzmaurice DA, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7:e017157. https://doi.org/10.1136/bmjop en-2017-017157

305. Niederdockl J, Simon A, Schnaubelt S, Schuetz N, Laggner R, Sulzgruber P, et al. Cardiac biomarkers predict mortality in emergency patients presenting with atrial fibrillation. Heart. 2019;105:482-8. https://doi.org/10.1136/heart jnl-2018-313145

306. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, et al.;the ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018;39(6):477-85. https://doi.org/10.1093/eurheartj/ehx584

307. Esteve-Pastor MA, Roldan V, Rivera-Caravaca JM, Ramirez-Macias I, Lip GYH, Marin F. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost. 2019. https://doi.org/10.1055/s-0039-1696955

308. Selvanayagam JB, Hartshorne T, Billot L, Grover S, Hillis GS, Jung W, et al. Cardiovascular magnetic resonance-GUIDED management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): study protocol for a randomized controlled trial. Ann Noninvasive Electrocardiol. 2017;22:e12420. https://doi.org/10.1111/anec.12420

309. Chang TY, Lip GYH, Chen SA, Chao TF. Importance of risk reassessment in patients with atrial fibrillation in guidelines: assessing risk as a dynamic process. Can J Cardiol. 2019;35:611-8. https://doi.org/10.1016/j.cjca.2019.01.018

310. Asunción Esteve-Pastor M, Miguel Rivera-Caravaca J, Roldan V, Vicente V, Valdes M, Marin F, et al. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. Thromb Haemost. 2017;117:1848-58. https://doi.org/10.1160/TH17-07-0478

311. Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, Valdes M, Vicente V, Lip GYH, et al. Long-term stroke risk prediction in patients with atrial fibrillation: comparison of the ABC-stroke and CHA₂DS₂-VASc scores. J Am Heart Assoc. 2017;6(7):1-9. e006490

312. Kaarisalo MM, Immonen-Raiha P, Marttila RJ, Salomaa V, Kaarsalo E, Salmi K, et al. Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. Stroke. 1997;28:311-5. https://doi.org/10.1161/01.STR.28.2.311

313. Gao H, Sun X, Li W, Gao Q, Zhang J, Zhang Y, et al. Development and validation of a risk score to predict 30-day mortality in patients with atrial fibrillation-related stroke: GPS-GF score. Neurol Res. 2018;40:532-40. https://doi.org/10.1080/01616 412.2018.1451431

314. Reinier K, Marijon E, Uy-Evanado A, Teodorescu C, Narayanan K, Chugh H, et al. The association between atrial fibrillation and sudden cardiac death: the relevance of heart failure. JACC Heart Fail. 2014;2:221-7. https://doi.org/10.1016/j.jchf.2013.12.006

315. Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Dahlof B, et al. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circ Arrhythm Electrophysiol. 2013;6:243-51. https://doi.org/10.1161/CIRCEP.112.977777

316. Chen LY, Sotoodehnia N, Bůžková P, Lopez FL, Yee LM, Heckbert SR, et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med. 2013;173:29-35. https://doi.org/10.1001/2013.jamainternmed.744

317. Rattanawong P, Upala S, Riangwiwat T, Jaruvongvanich V, Sanguankeo A, Vutthikravit W, et al. Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2018;51:91-104. https://doi.org/10.1007/s10840-017-0308-9

318. Chao TF, Liu CJ, Tuan TC, Chen SJ, Chen TJ, Lip GYH, et al. Risk and prediction of sudden cardiac death and ventricular arrhythmias for patients with atrial fibrillation—a Nationwide Cohort Study. Sci Rep. 2017;7:46445. https://doi.org/10.1038/srep46445

319. Eisen A, Ruff CT, Braunwald E, Nordio F, Corbalan R, Dalby A, et al. Sudden cardiac death in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016;5(7):1-12. e003735.

320. Roy D, Talajic M, Mattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-77. https://doi.org/10.1056/NEJMoa0708789

321. Arbelo E, Brugada J, Hindricks G, Maggioni A, Tavazzi L, Vardas P, et al.;on behalf of the Atrial Fibrillation Ablation Pilot Study Investigators. ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace. 2012;14:1094-103. https://doi.org/10.1093/europace/eus153

322. Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P, et al.;on the behalf of the Atrial Fibrillation Ablation Pilot Study Investigators. The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J. 2014;35:1466-78. https://doi.org/10.1093/eurheartj/ehu001

323. Arbelo E, Brugada J, Blomstrom-Lundqvist C, Laroche C, Kautzner J, Pokushalov E, et al.;on the behalf of the ESC-EHRA Atrial Fibrillation Ablation Long-term Registry Investigators. Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. Eur Heart J. 2017;38:1303-16. https://doi.org/10.1093/eurheartj/ehw564

324. De Greef Y, Stroker E, Schwagten B, Kupics K, De Cocker J, Chierchia GB, et al. Complications of pulmonary vein isolation in atrial fibrillation: predictors and comparison between four different ablation techniques: results from the Middelheim PVI-registry. Europace. 2018;20:1279-86. https://doi.org/10.1093/europace/eux233

325. Steinbeck G, Sinner MF, Lutz M, Muller-Nurasyid M, Kaab S, Reinecke H. Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014. Eur Heart J. 2018;39:4020-9. https://doi.org/10.1093/eurheartj/ehy452

326. Fink T, Metzner A, Willems S, Eckardt L, Ince H, Brachmann J, et al. Procedural success, safety and patients satisfaction after second ablation of atrial fibrillation in the elderly: results from the German
Ablation Registry. Clin Res Cardiol. 2019;108:1354-63. https://doi.org/10.1007/s00392-019-01471-5

327. Bunch TJ, May HT, Bair TL, Anderson JL, Crandall BG, Cutler MJ, et al. Long-term natural history of adult Wolff-Parkinson-White syndrome patients treated with and without catheter ablation. Circ Arrhythm Electrophysiol. 2015;8:1465-71. https://doi.org/10.1161/CIRCEP.115.003013

328. Haissaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659-66. https://doi.org/10.1056/NEJM19980903391003

329. Ebert M, Stegmann C, Kosiuk J, Dinov B, Richter S, Predictors AA, et al. and outcome of cardioversion failure early after atrial fibrillation ablation. Europace. 2018;20:1428-34. https://doi.org/10.1093/europace/eux327

330. Deng H, Bai Y, Shantsila A, Fauchier L, Potpara TS, Lip GY. Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review. Clin Res Cardiol. 2017;106:813-23. https://doi.org/10.1007/s00392-017-1123-0

331. Degiovanni A, Boggio E, Prenna E, Sartori C, De Vecchi F, Marino PN.; et al. Association between left atrial phasic conduit function and early atrial fibrillation recurrence in patients undergoing electrical cardioversion. Clin Res Cardiol. 2018;107:329-37. https://doi.org/10.1007/s00392-017-1188-9

332. Mujović N, Marinković M, Lip GY, Potpara TS. Predicting recurrent atrial fibrillation after catheter ablation. Europace. 2018;20(FI_3):f460-1.

333. Sepehri Shamloo A, Dagres N, Dinov B, Sommer P, Husser-Bollmann D, Bollmann A, et al. Is epicardial fat tissue associated with atrial fibrillation recurrence after ablation? A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2019;22: 132-8. https://doi.org/10.1016/j.ijcha.2019.01.003

334. Mesquita J, Ferreira AM, Cavaco D, Moscoso Costa F, Carmo P, Marques H, et al. Development and validation of a risk score for predicting atrial fibrillation recurrence after a first catheter ablation procedure-ATLAS score. Europace. 2018;20: f428-f435. https://doi.org/10.1093/europace/eux265

335. Winkle RA, Jarman JWE, Mead RH, Engel G, Kong MH, Fleming W, et al. Predicting atrial fibrillation ablation outcome: the CAAP-AF score. Heart Rhythm. 2016;13: 2119-25. https://doi.org/10.1016/j.hrthm.2016.07.018

336. Canpolat U, Aytemir K, Yorgun H, Şahiner L, Kaya EB, Oto A. A proposal for a new scoring system in the prediction of catheter ablation outcomes: Promising results from the Turkish Cryoablation Registry. Int J Cardiol. 2013;169:201-6. https://doi.org/10.1016/j.ijcard.2013.08.097

337. Oacute Jcik M, Berkowitsch A, Greiss H, Zaltsberg S, Pajitnev D, Deubner N, et al. Repeated catheter ablation of atrial fibrillation. Circ J. 2013;77: 2271-9. https://doi.org/10.1253/circj.CJ-13-0308

338. Kornej J, Buttner P, Sommer P, Dagres N, Dinov B, Schumacher K, et al. Prediction of electro-anatomical substrate using APPLE score and biomarkers. Europace. 2019;21:54-9. https://doi.org/10.1093/europace/euy120

339. Buttner P, Schumacher K, Dinov B, Zeynalova S, Sommer P, Bollmann A, et al. Role of NT-proANP and NT-proBNP in patients with atrial fibrillation: association with atrial fibrillation progression phenotypes. Heart Rhythm. 2018;15:1132-7. https://doi.org/10.1016/j.hrthm.2018.03.021

340. Kornej J, Hindricks G, Shoemaker MB, Husser D, Arya A, Sommer P, et al. The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. Clin Res Cardiol. 2015;104: 871-6. https://doi.org/10.1007/s00392-015-0856-x

341. Kornej J, Hindricks G, Arya A, Sommer P, Husser D, Bollmann A. The APPLE Score—a novel score for the prediction of rhythm outcomes after repeat catheter ablation of atrial fibrillation. PLoS ONE. 2017;12:e0169933. https://doi.org/10.1371/journal.pone.0169933

342. Kornej J, Schumacher K, Dinov B, Kosich F, Sommer P, Arya A, et al. Prediction of electro-anatomical substrate and arrhythmia recurrences using APPLE, DR-FLASH and MB-LATER scores in patients with atrial fibrillation undergoing catheter ablation. Sci Rep. 2018;8:12686. https://doi.org/10.1038/s41598-018-31133-x

343. Kosiuk J, Dinov B, Kornej J, Acou WJ, Schonbauer R, Fiedler L, et al. Prospective, multicenter validation of a clinical risk score for left atrial arrhythmogenic substrate based on voltage analysis: DR-FLASH score. Heart Rhythm. 2015;12:2207-12. https://doi.org/10.1016/j.hrthm.2015.07.003

344. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32-8. https://doi.org/10.1161/CIRCEP.109.859116

345. Lee G, Sparks PB, Morton JB, Kistler PM, Vohra JK, Medi C, et al. Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center. J Cardiovasc Electrophysiol. 2011;22:163-8. https://doi.org/10.1111/j.1540-8167.2010.01870.x

346. Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation. 2013;128:2104-12. https://doi.org/10.1161/CIRCULATIONAHA.113.003862

347. Tripathi B, Arora S, Kumar V, Abdelrahman M, Lahewala S, Dave M, et al. Temporal trends of in-hospital complications associated with catheter ablation of atrial fibrillation in the United States: an update from Nationwide Inpatient Sample database (2011-2014). J Cardiovasc Electrophysiol. 2018;29:715-24. https://doi.org/10.1111/jce.13471

348. Voskoboinik A, Sparks PB, Morton JB, Lee G, Joseph SA, Hawson JJ, et al. Low rates of major complications for radiofrequency ablation of atrial fibrillation maintained over 14 years: a single centre experience of 2750 consecutive cases. Heart Lung Circ. 2018;27:976-83. https://doi.org/10.1016/j.hlc.2018.01.002

349. Shamloo AS, Dagres N, Arya A, Hindricks G. Atrial fibrillation: a review of modifiable risk factors and preventive strategies. Rom J Intern Med. 2019;57:99-109. https://doi.org/10.2478/rjim-2018-0045

350. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222-31. https://doi.org/10.1016/j.jacc.2014.09.028

351. Providencia R, Adragao P, de Asmundis C, Chun J, Chierchia G, Defaye P, et al. Impact of body mass index on the outcomes of catheter ablation of atrial fibrillation: a European Observational Multicenter Study. J Am Heart Assoc. 2019;8:e012253.

352. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, et al. Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med. 2020;382:20-8. https://doi.org/10.1056/NEJMoa1817591

353. Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol.
2003;42:185-97. https://doi.org/10.1016/S0735-1097(03)00577-1

354. Mansour M, Heist EK, Agarwal R, Bunch TJ, Karst E, Ruskin JN, et al. Stroke and cardiovascular events after ablation or antiarrhythmic drugs for treatment of patients with atrial fibrillation. Am J Cardiol. 2018;121:1192-9. https://doi.org/10.1016/j.amjca.rd.2018.01.043

355. Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol. 2010;55:735-43. https://doi.org/10.1016/j.jacc.2009.11.039

356. Cox JL, Ad N, Palazzo T, Fitzpatrick S, Suyderhoud JP, DeGroot KW, et al. Current status of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg. 2000;12:15-9. https://doi.org/10.1016/S1043-0679(00)70011-6

357. La Meir M, Gelsomino S, Luca F, Pison L, Colella A, Lorusso R, et al. Minimal invasive surgery for atrial fibrillation: an updated review. Europace. 2013;15:170-82. https://doi.org/10.1093/europace/eus216

358. Gaynor SL, Diodato MD, Prasad SM, Ishii Y, Schuessler RB, Bailey MS, et al. A prospective, single-center clinical trial of a modified Cox Maze procedure with bipolar radiofrequency ablation. J Thorac Cardiovasc Surg. 2004;128:535-42. https://doi.org/10.1016/j.jtcvs.2004.02.044

359. Fumagalli S, Chen J, Dobreanu D, Madrid AH, Tilz R, Dagres N. The role of the Arrhythmia Team, an integrated, multidisciplinary approach to treatment of patients with cardiac arrhythmias: results of the European Heart Rhythm Association survey. Europace. 2016;18:623-7. https://doi.org/10.1093/europace/euw090

360. Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB Jr, O'Brien SM, et al. Atrial fibrillation correction surgery: lessons from the Society of Thoracic Surgeons National Cardiac Database. Ann Thorac Surg. 2008;85:909-14. https://doi.org/10.1016/j.athoracsur.2007.10.097

361. Khurram IM, Maqbool F, Berger RD, Marine JE, Spragg DD, Ashikaga H, et al. Association between left atrial stiffness index and atrial fibrillation recurrence in patients undergoing left atrial ablation. Circ Arrhythm Electrophysiol. 2016;9(3):1-9. e003163. https://doi.org/10.1161/CIRCEP.115.003163

362. Chen MC, Chang JP, Chang HW. Preoperative atrial size predicts the success of radiofrequency Maze procedure for permanent atrial fibrillation in patients undergoing concomitant valvular surgery. Chest. 2004;125:2129-34. https://doi.org/10.1378/chest.125.6.2129

363. Sunderland N, Maruthappu M, Nagendran M. What size of left atrium significantly impairs the success of Maze surgery for atrial fibrillation? Interact Cardiovasc Thorac Surg. 2011;13:332-8. https://doi.org/10.1510/icvts.2011.271999

364. Chaiyaroj S, Ngarmukos T, Lertsithichai P. Predictors of sinus rhythm after radiofrequency Maze and mitral valve surgery. Asian Cardiovasc Thorac Ann. 2008;16:292-7. https://doi.org/10.1177/021849230801600407

365. Gillinov AM, Bhavani S, Blackstone EH, Rajeswaran J, Svensson LG, Navia JL, et al. Surgery for permanent atrial fibrillation: impact of patient factors and lesion set. Ann Thorac Surg. 2006;82:502-13; discussion 13-4. https://doi.org/10.1016/j.athoracsur.2006.02.030

366. Beukema WP, Sie HT, Misier AR, Delnoy PP, Wellens HJ, Elvan A. Predictive factors of sustained sinus rhythm and recurrent atrial fibrillation after a radiofrequency modified Maze procedure. Eur J Cardio-Thorac Surg. 2008;34:771-5. https://doi.org/10.1016/j.ejcts.2008.07.026

367. Boersma LVA, Castella M, van Boven WimJan, Berruezo A, Yilmaz A, Nadal M, et al. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial.

Circulation. 2012;125:23-30. https://doi.org/10.1161/CIRCULATIONAHA.111.074047

368. Damiano RJ Jr, Schwartz FH, Bailey MS, Maniar HS, Munfakh NA, Moon MR, et al. The Cox Maze IV procedure: predictors of late recurrence. J Thorac Cardiovasc Surg. 2011;141:113-21. https://doi.org/10.1016/j.jtcvs.2010.08.067

369. Edgerton JR, McClelland JH, Duke D, Gerdisch MW, Steinberg BM, Bronleewe SH, et al. Minimally invasive surgical ablation of atrial fibrillation: six-month results. J Thorac Cardiovasc Surg. 2009;138:109-13; discussion 14. https://doi.org/10.1016/j.jtcvs.2008.09.080

370. Myerburg RJ, Mitrani R, Interian A Jr, Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation. 1998;97:1514-21. https://doi.org/10.1161/01.CIR.97.15.1514

371. Disertori M, Rigoni M, Pace N, Casolo G, Mase M, Gonzini L, et al. Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction: a meta-analysis. JACC Cardiovasc Imaging. 2016;9:1046-55. https://doi.org/10.1016/j.jcmg.2016.01.033

372. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-8. https://doi.org/10.1053/euhj.2000.2476

373. Disertori M, Mase M, Rigoni M, Nollo G, Ravelli F. heart rate turbulence is a powerful predictor of cardiac death and ventricular arrhythmias in postmyocardial infarction and heart failure patients: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2016;9. https://doi.org/10.1161/CIRCEP.116.004610

374. Morin DP, Zacks ES, Mauer AC, Ageno S, Janik M, Markowitz SM, et al. Effect of bundle branch block on microvolt T-wave alternans and electrophysiologic testing in patients with ischemic cardiomyopathy. Heart Rhythm. 2007;4:904-12. https://doi.org/10.1016/j.hrthm.2007.02.027

375. Biering-Sorensen T, Olsen FJ, Storm K, Fritz-Hansen T, Olsen NT, Jons C, et al. Prognostic value of tissue Doppler imaging for predicting ventricular arrhythmias and cardiovascular mortality in ischaemic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2016;9:e002951. https://doi.org/10.1161/CIRCEP.115.002951

376. Bui AH, Cannon CP, Steg PG, Storey RF, Husted S, Guo J, et al. Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circ Arrhythm Electrophysiol. 2016;9:e002951. https://doi.org/10.1161/CIRCEP.115.002951

377. Prystowsky EN, Nisam S. Prophylactic implantable cardioverter defibrillator trials: MUSTT, MADIT, and beyond. Multicenter Unsustained Tachycardia Trial. Multicenter Automatic Defibrillator Implantation Trial. Am J Cardiol. 2000;86:1214-5. a5. https://doi.org/10.1016/S0002-9149(00)01205-4

378. Goldberger JJ, Subacius H, Patel T, Cunnane R, Kadish AH. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2014;63:1879-89. https://doi.org/10.1016/j.jacc.2013.12.021

379. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874-9. https://doi.org/10.1001/jama.292.23.2874

380. Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic
cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7:250–8. https://doi.org/10.1161/CIRCI MAGING.113.001144

381. Marume K, Noguchi T, Tateishi E, Morita Y, Kamakura T, Ishibashi K, et al. Mortality and sudden cardiac death risk stratification using the noninvasive combination of wide QRS duration and late gadolinium enhancement in idiopathic dilated cardiomyopathy. Circ Arrhythm Electrophysiol. 2018;11:e006233. https://doi.org/10.1161/CIRCEP.117.006233

382. Tung R, Bauer B, Schelbert H, Lynch JP, Auerbach M, Gupta P, et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis. Heart Rhythm. 2015;12(12):2488–98. https://doi.org/10.1016/j. hrthm.2015.08.014

383. Heymans S, Eriksson U, Lehtonen J, Cooper LT Jr. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol. 2016;68:2348–64. https://doi.org/10.1016/j. jacc.2016.09.937

384. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm. 2012;9:884–91. https://doi.org/10.1016/j. hrthm.2012.02.010

385. Smedema J-P, Snoep G, van Kroonenburgh MPG, van Geuns R-J, Dassen WRM, Gorgels APM, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683–90. https://doi.org/10.1016/j.jacc.2005.01.047

386. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969–77. https://doi.org/10.1161/CIRCU LATIONAHA.109.851352

387. Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2016;9:e003738. https://doi.org/10.1161/CIRCI MAGING.115.003738

388. Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, et al. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY study. J Am Coll Cardiol. 2017;70:1977–87. https://doi.org/10.1016/j. jacc.2017.08.044

389. Grani C, Eichhorn C, Biere L, Murthy VL, Agarwal V, Kaneko K, et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol. 2017;70:1964–76. https://doi.org/10.1016/j. jacc.2017.08.050

390. Mahfoud F, Gartner B, Kindermann M, Ukena C, Gadomski K, Klingel K, et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J. 2011;32:897–903. https://doi.org/10.1093/eurheartj/ehq493

391. Ichinose A, Otani H, Oikawa M, Takase K, Saito H, Shimokawa H, et al. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. Am J Roentgenol. 2008;191:862–9. https://doi.org/10.2214/ AJR.07.3089

392. Van Hare GF, Javitz H, Carmelli D, Saul JP, Tanel RE, Fischbach PS, et al. Prospective assessment after pediatric cardiac ablation: demographics, medical profiles, and initial outcomes. J Cardiovasc Electrophysiol. 2004;15:759–70. https://doi.org/10.1046/j.1540-8167.2004.03645.x

393. Khairy P, Van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI, et al. PACES/HRS expert consensus statement on the

recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRHS), and the International Society for Adult Congenital Heart Disease (ISACHD). Can J Cardiol. 2014;30:e1–63. https://doi.org/10.1016/j.cjca.2014.09.002

394. Brugada J, Blom N, Sarquella-Brugada G, Blomstrom-Lundqvist C, Deanfield J, Janousek J, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15:1337–82. https://doi.org/10.1093/europace/eut082

395. Harrison DA, Harris L, Siu SC, MacLoghlin CJ, Connelly MS, Webb GD, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol. 1997;30:1368–73. https://doi.org/10.1016/S0735-1097(97)00316-1

396. Knauth AL, Gauvreau K, Powell AJ, Landzberg MJ, Walsh EP, Lock JE, et al. Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair. Heart. 2008;94:211–6. https://doi.org/10.1136/hrt.2006.104745

397. Khairy P, Landzberg MJ, Gatzoulis MA, Lucron H, Lambert J, MarçOn FOIS, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation. 2004;109:1994–2000. https://doi.org/10.1161/01.CIR.00001 26495.11040.BD

398. Hernandez-Madrid A, Paul T, Abrams D, Aziz PF, Blom NA, Chen J, et al. Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAEGE. Europace. 2018;20:1719–53. https://doi.org/10.1093/europace/eux380

399. Vehmeijer JT, Koyak Z, Bokma JP, Budts W, Harris L, Mulder BJM, et al. Sudden cardiac death in adults with congenital heart disease: does QRS-complex fragmentation discriminate in structurally abnormal hearts? Europace. 2018;20:f122–f128. https://doi.org/10.1093/europace/eux044

400. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. HRS/ EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmogenic syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10:1932–63. https://doi.org/10.1016/j. hrthm.2013.05.014

401. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al. HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019. https://doi.org/10.1016/j. hrthm.2019.09.019

402. Roston TM, Yuchi Z, Kannankeril PJ, Hathaway J, Vinocur JM, Etheridge SP, et al. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry. Europace. 2018;20:541–7. https://doi.org/10.1093/europace/euw389

403. Schwartz PJ, Ackerman MJ. The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. Eur Heart J. 2013;34:3109–16. https://doi.org/10.1093/eurheartj/eht089

404. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, et al. Incidence and risk factors of arrhythmic
events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426-34. https://doi.org/10.1161/CIRCU LATIONAHA.108.829267

405. Adler A, Rosso R, Chorin E, Havakuk O, Antzelevitch C, Viskin S. Risk stratification in Brugada syndrome: clinical characteristics, electrocardiographic parameters, and auxiliary testing. Heart Rhythm. 2016;13:299-310. https://doi.org/10.1016/j. hrthm.2015.08.038

406. Sieira J, Conte G, Cicente G, Chierchia GB, Casado-Arroyo R, Baltogiannis G, et al. A score model to predict risk of events in patients with Brugada Syndrome. Eur Heart J. 2017;38:1756-63. https://doi.org/10.1093/eurheartj/ehx119

407. Yamagata K, Horie M, Aiba T, Ogawa S, Aizawa Y, Ohe T, et al. Genotype-phenotype correlation of SCN5A mutation for the clinical and electrocardiographic characteristics of probands with Brugada syndrome: a Japanese Multicenter Registry. Circulation. 2017;135:2255-70. https://doi.org/10.1161/CIRCULATIONAHA. 117.027983

408. O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35:2010-20. https://doi.org/10.1093/eurheartj/ eht439

409. Priori SG, Reviewers D, Wilde AA, Horie M, Cho Y, Behr ER, et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace. 2013;15:1389-406. https://doi.org/10.1093/europace/eut272

410. van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans- van Ast JF, van der Kooi AJ et al. Risk factors for malignant ventricular arrhythmias in Lamin A/C mutation carriers a European cohort study. J Am Coll Cardiol. 2012;59:493-500. https://doi. org/10.1016/j.jacc.2011.08.078

411. van Rijsingen IA, van der Zwaag PA, Groeneweg JA, Nannenberg EA, Jongbloed JD, Zwinderman AH, et al. Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet. 2014;7:455-65. https://doi.org/10.1161/ CIRCGENETICS.113.000374

412. Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricu- lar cardiomyopathy. N Engl J Med. 2017;376:61-72. https://doi. org/10.1056/NEJMra1509267

413. Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T, et al. EHRA/HRS/APHRS expert consensus on ventric- ular arrhythmias. Heart Rhythm. 2014;11:e166-e196. https://doi. org/10.1016/j.hrthm.2014.07.024

414. Calkins H, Corrado D, Marcus F. Risk stratification in ar- rhythmogenic right ventricular cardiomyopathy. Circulation. 2017;136:2068-82. https://doi.org/10.1161/CIRCULATIONAHA. 117.030792

415. Wang W, Orgeron G, Tichnell C, Murray B, Crosson J, Monfredi O, et al. Impact of exercise restriction on arrhythmic risk among patients with arrhythmogenic right ventricular cardio- myopathy. J Am Heart Assoc. 2018;7. https://doi.org/10.1161/ JAHA.118.008843

416. Sawant AC, Te Riele AS, Tichnell C, Murray B, Bhonsale A, Tandri H, et al. Safety of American Heart Association-recommended min- imum exercise for desmosomal mutation carriers. Heart Rhythm. 2016;13:199-207. https://doi.org/10.1016/j.hrthm.2015.08.035

417. Philips B, Madhavan S, James C, Tichnell C, Murray B, Needleman M, et al. High prevalence of catecholamine-facilitated focal ven- tricular tachycardia in patients with arrhythmogenic right ven- tricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2013;6:160-6. https://doi.org/10.1161/CIRCEP.112.975441

418. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Bohm M, et al. Proposal for a revised definition of dilated cardiomyopathy,

hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37:1850-8. https://doi.org/10.1093/eurheartj/ehv727

419. Deac M, Alpendurada F, Fanaie F, Vimal R, Carpenter JP, Dawson A, et al. Prognostic value of cardiovascular magnetic resonance in patients with suspected arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol. 2013;168:3514-21. https://doi. org/10.1016/j.ijcard.2013.04.208

420. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardio- myopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010;31:806-14. https://doi.org/10.1093/ eurheartj/ehq025

421. Denis A, Sacher F, Derval N, Martin R, Lim HS, Pambrun T, et al. Arrhythmogenic response to isoproterenol testing vs. exercise testing in arrhythmogenic right ventricular cardiomyopathy pa- tients. Europace. 2018;20:f30-f36. https://doi.org/10.1093/ europace/euy007

422. Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JD, et al. Impact of genotype on clinical course in ar- rhythmogenic right ventricular dysplasia/cardiomyopathy-associ- ated mutation carriers. Eur Heart J. 2015;36:847-55. https://doi. org/10.1093/eurheartj/ehu509

423. Quarta G, Syrris P, Ashworth M, Jenkins S, Zuborne Alapi K, Morgan J, et al. Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2012;33:1128-36. https://doi.org/10.1093/eurheartj/ehr451

424. Gali WL, Sarabanda AV, Baggio JM, Silva EF, Gomes GG. Junqueira LF. Predictors of mortality and heart transplantation in pa- tients with Chagas' cardiomyopathy and ventricular tachycardia treated with implantable cardioverter-defibrillators. Europace. 2019;21:1070-8. https://doi.org/10.1093/europace/euz012

425. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C, et al. Systematic review: implantable cardioverter de- fibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007;147:251-62. https://doi.org/10.7326/0003- 4819-147-4-200708210-00007

426. Kolodziejczak M, Andreotti F, Kowalewski M, Buffon A, Ciccone MM, Parati G, et al. Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic car- diomyopathy: a systematic review and meta-analysis. Ann Intern Med. 2017;167:103-11. https://doi.org/10.7326/M17-0120

427. Lee DS, Green LD, Liu PP, Dorian P, Newman DM, Grant FC, et al. Effectiveness of implantable defibrillators for prevent- ing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol. 2003;41:1573-82. https://doi.org/10.1016/S0735-1097 (03)00253-5

428. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51:1357-65. https://doi.org/10.1016/j. jacc.2007.09.073

429. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior appropriate implantable cardio- converter-defibrillator therapy: a competing risk study. Circulation. 2008;117:1918-26. https://doi.org/10.1161/CIRCULATIO NAHA.107.742155

430. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009-17. https://doi. org/10.1056/NEJMoa071098

431. Blom LJ, Visser M, Christiaans I, Scholten MF, Bootsma M, van den Berg MP, et al. Incidence and predictors of implantable car- dioverter-defibrillator therapy and its complications in idiopathic
ventricular fibrillation patients. Europace. 2019;21:1519-26.
https://doi.org/10.1093/europace/euz151

432. Milman A, Hochstadt A, Andorin A, Gourraud JB, Sacher F, Mabo P, et al. Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Europace. 2019;21:796-802. https://doi.org/10.1093/europace/euy301

433. Dougherty CM, Hunziker J. Predictors of implantable cardioverter defibrillator shocks during the first year. J Cardiovasc Nurs. 2009;24:21-8. quiz 9-30. https://doi.org/10.1097/01.JCN.00003 17473.42801.a8

434. Konstantino Y, Shafat T, Novack V, Novack L, Amit G. Incidence of implantable cardioverter defibrillator therapy and mortality in primary and secondary prevention of sudden cardiac death. Isr Med Assoc J. 2015;17:760-3.

435. Nagahara D, Fujito T, Mochizuki A, Shimoshige S, Hashimoto A, Miura T. Predictors of appropriate ICD therapy in Japanese patients with structural heart diseases: a major role of prior sustained ventricular tachycardia in secondary prevention. J Arrhythmia. 2018;34:527-35. https://doi.org/10.1002/joa3.12086

436. van Welsenes GH, van Rees JB, Borleffs CJ, Cannegieter SC, Bax JJ, van Erven L, et al. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace. 2011;13:389-94. https://doi.org/10.1093/europace/euq494

437. Zareba W, Moss AJ, Jackson Hall W, Wilber DJ, Ruskin JN, McNitt S, et al.; MADIT II Investigators. Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol. 2005;16:1265-70. https://doi.org/10.1111/j.1540-8167.2005.00224.x

438. Santangeli P, Pelargonio G, Dello Russo A, Casella M, Bisceglia C, Bartoletti S, et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm. 2010;7:876-82. https://doi.org/10.1016/j.hrthm.2010.03.042

439. MacFadden DR, Crystal E, Krahn AD, Mangat I, Healey JS, Dorian P, et al. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database. Ann Intern Med. 2012;156:195-203. https://doi.org/10.7326/0003-4819-156-3-201202070-00007

440. Seegers J, Conen D, Jung K, Bergau L, Dorenkamp M, Luthje L, et al. Sex difference in appropriate shocks but not mortality during long-term follow-up in patients with implantable cardioverter-defibrillators. Europace. 2016;18:1194-202. https://doi.org/10.1093/europace/euv361

441. van der Heijden AC, Thijssen J, Borleffs CJ, van Rees JB, Hoke U, van der Velde ET, et al. Gender-specific differences in clinical outcome of primary prevention implantable cardioverter defibrillator recipients. Heart. 2013;99:1244-9. https://doi.org/10.1136/heartjnl-2013-304013

442. Wijers SC, van der Kolk BY, Tuinenburg AE, Doevendans PA, Vos MA, Meine M. Implementation of guidelines for implantable cardioverter-defibrillator therapy in clinical practice: which patients do benefit? Neth Heart J. 2013;21:274-83. https://doi.org/10.1007/s12471-013-0407-x

443. Conen D, Arendacka B, Rover C, Bergau L, Munoz P, Wijers S, et al. gender differences in appropriate shocks and mortality among patients with primary prophylactic implantable cardioverter-defibrillators: systematic review and meta-analysis. PLoS ONE. 2016;11:e0162756. https://doi.org/10.1371/journal.pone.0162756

444. Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169:1500-6. https://doi.org/10.1001/archinternmed.2009.255

445. Providencia R, Marijon E, Lambiase PD, Bouzeman A, Defaye P, Klug D, et al. Primary prevention implantable cardioverter defibrillator (ICD) therapy in women-data from a Multicenter French Registry. J Am Heart Assoc. 2016;5(2):1-10. e002756.

446. Borleffs CJ, van Rees JB, van Welsenes GH, van der Velde ET, van Erven L, Bax JJ, et al. Prognostic importance of atrial fibrillation in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:879-85. https://doi.org/10.1016/j.jacc.2009.09.053

447. Darma A, Nedios S, Kosiuk J, Richter S, Doering M, Arya A, et al. Differences in predictors of implantable cardioverter-defibrillator therapies in patients with ischaemic and non-ischaemic cardiomyopathies. Europace. 2016;18:405-12. https://doi.org/10.1093/europace/euv138

448. Gronefeld GC, Mauss O, Li YG, Klingenheben T. Hohnloser SH. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study. J Cardiovasc Electrophysiol. 2000;11:1208-14. https://doi.org/10.1046/j.1540-8167.2000.01208.x

449. Rienstra M, Smit MD, Nieuwland W, Tan ES, Wiesfeld AC, Anthony RL, et al. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator. Am Heart J. 2007;153:120-6. https://doi.org/10.1016/j.ahj.2006.09.010

450. Chang IC, Agamawi YM, Austin E, Adkisson WO, Roukoz H, von Wald LN, et al. Usefulness of atrial fibrillation as a marker for adverse cardiovascular outcomes in both primary and secondary prevention in patients with implantable cardioverter-defibrillators. Am J Cardiol. 2016;118:1497-502. https://doi.org/10.1016/j.amjcard.2016.08.016

451. van Rees JB, Borleffs CJ, de Bie MK, Stijnen T, van Erven L, Bax JJ, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011;57:556-62. https://doi.org/10.1016/j.jacc.2010.06.059

452. Yang JH, Byeon K, Yim HR, Park JW, Park SJ, Huh J, et al. Predictors and clinical impact of inappropriate implantable cardioverter-defibrillator shocks in Korean patients. J Korean Med Sci. 2012;27:619-24. https://doi.org/10.3346/jkms.2012.27.6.619

453. Deyell MW, Qi A, Chakrabarti S, Yeung-Lai-Wah JA, Tung S, Khoo C, et al. Prognostic impact of inappropriate defibrillator shocks in a population cohort. Heart. 2013;99:1250-5. https://doi.org/10.1136/heartjnl-2012-303407

454. Fernandez-Cisnal A, Arce-Leon A, Arana-Rueda E, Rodriguez-Manero M, Gonzalez-Cambeiro C, Moreno-Arribas J, et al. Analyses of inappropriate shocks in a Spanish ICD primary prevention population: predictors and prognoses. Int J Cardiol. 2015;195:188-94. https://doi.org/10.1016/j.ijcard.2015.05.146

455. Mustafa U, Dherange P, Reddy R, DeVillier J, Chong J, Ihsan A, et al. Atrial fibrillation is associated with higher overall mortality in patients with implantable cardioverter-defibrillator: a systematic review and meta-analysis. J Am Heart Assoc. 2018;7:e010156. https://doi.org/10.1161/JAHA.118.010156

456. Powell BD, Saxon LA, Boehmer JP, Day JD, Gilliam FR, Heidenreich PA, et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol. 2013;62:1674-9. https://doi.org/10.1016/j.jacc.2013.04.083
457. Bergau L, Willems R, Sprenkeler DJ, Fischer TH, Flevari P, Hasenfuß G, et al. Differential multivariable risk prediction of appropriate shock versus competing mortality—a prospective cohort study to estimate benefits from ICD therapy. Int J Cardiol. 2018;272:102–7. https://doi.org/10.1016/j.ijcard.2018.06.103

458. Lelakowski J, Piekarz J, Rydlewska A, Majewski J, Senderek T,Żąbek A, et al. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-isaemic dilated cardiomyopathy. Kardiologia Polska. 2012;70:1264–75.

459. Weeke P, Johansen JB, Jorgensen OD, Nielsen JC, Moller M, Videbaek R, et al. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register. Europace. 2013;15:1150–7. https://doi.org/10.1093/europace/eut017

460. Schaer B, Kuhne M, Reichlin T, Osswald S. Sticherling C. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication. Europace. 2016;18:227–31. https://doi.org/10.1093/europace/euv188

461. Lee AKY, Andrade J, Hawkins NM, Alexander G, Bennett MT, Chakrabarti S, et al. Outcomes of untreated frequent premature ventricular complexes with normal left ventricular function. Heart. 2019;105:1408–13. https://doi.org/10.1136/heart.jnl-2019-314922

462. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7:865–9. https://doi.org/10.1016/j.hrthm.2010.03.036

463. Duffee DF, Shen WK, Smith HC. Suppression of frequent premature ventricular contractions and improvement of left ventricular function in patients with presumed idiopathic dilated cardiomyopathy. Mayo Clin Proc. 1998;73:430–3. https://doi.org/10.1016/S0025-6196(11)63724-5

464. Hasdemir C, Ulucan C, Yavuzgil O, Yuksel A, Kartal Y, Simsek E, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol. 2011;22:663–8. https://doi.org/10.1111/j.1540-8167.2010.01986.x

465. Huizar JF, Ellenbogen KA, Tan AY, Kaszala K. Induced cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2328–44. https://doi.org/10.1016/j.jacc.2019.02.045

466. Tsuji A, Nagashima M, Hasegawa S, Nagai N, Nishibata K, Goto M, et al. Long-term follow-up of idiopathic ventricular arrhythmias in otherwise normal children. Jpn Circ J. 1995;59:654–62. https://doi.org/10.1253/jcj.59.654

467. Hasdemir C, Yuksel A, Camli D, Kartal Y, Simsek E, Musayev O, et al. Late gadolinium enhancement CMR in patients with tachycardia-induced cardiomyopathy caused by idiopathic ventricular arrhythmias. Pacing Clin Electrophysiol. 2012;35:465–70. https://doi.org/10.1111/j.1540-8159.2011.03324.x

468. Penela D, Martinez M, Fernandez-Armenta J, Aguinaga L, Tercedor L, Ordonez A, et al. Influence of myocardial scar on the response to frequent premature ventricular complex ablation. Heart. 2018.

469. Bogun F, Crawford T, Chalfoun N, Kuhne M, Sarrazin JF, Wells D, et al. Relationship of frequent postinfarction premature ventricular complexes to the reentry circuit of scar-related ventricular tachycardia. Heart Rhythm. 2008;5:367–74. https://doi.org/10.1016/j.hrthm.2007.11.026

470. Ellis ER, Josephson ME. Heart failure and tachycardia-induced cardiomyopathy. Curr Heart Fail Rep. 2013;10:296–306. https://doi.org/10.1007/s11897-013-0150-z

471. Huizar J. Prospective assessment of premature ventricular contractions suppression in cardiomyopathy (PAPS) (NCT03228823). 2017. [cited 2020 Mar 18]. Available from https://clinicaltrials.gov/ct2/show/NCT03228823

472. Dabbagh GS, Bogun F. Predictors and therapy of cardiomyopathy caused by frequent ventricular ectopy. Curr Cardiol Rep. 2017;19:80. https://doi.org/10.1007/s11886-017-0887-1

473. Macatangay C, Viles-Gonzalez JF, Goldberger JJ. Role of cardiac imaging in evaluating risk for sudden cardiac death. *Cardiac Electrophysiol. Cardiac Electrophysiol Clin.* 2017;9:639–50. https://doi.org/10.1016/j.ccep.2017.08.001

474. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15:e190–e252. https://doi.org/10.1016/j.hrthm.2017.10.035

475. Proclemer A, Bongiorni MG, Dagres N, Sciaraffia E, Todd D. Blomstrom-Lundqvist C. How are European patients at risk of malignant arrhythmias or sudden cardiac death identified and informed about their risk profile: results of the European Heart Rhythm Association survey. Europace. 2015;17:994–8. https://doi.org/10.1093/europace/euv203

476. Deyell MW, Krahn AD, Goldberger JJ. Sudden cardiac death risk stratification. Circ Res. 2015;116:1907–18. https://doi.org/10.1161/CIRCRESAHA.116.304493

477. Fallavollita JA, Dare JD, Carter RL, Baldwa S, Canty JM Jr. Denervated myocardium is preferentially associated with sudden cardiac arrest in ischemic cardiomyopathy: a pilot competing risks analysis of cause-specific mortality. Circ Cardiovasc Imaging. 2017;10(8):1–11. e006446.

478. Deng D, Arevalo HJ, Prakosa A, Callans DJ, Trayanova NA. A feasibility study of arrhythmia risk prediction in patients with myocardial infarction and preserved ejection fraction. Europace. 2016;18:iv60–iv66. https://doi.org/10.1093/europace/euw351

479. Brugada P, Talajic M, Smeets J, Mulleneers R. Wellens HJ. The value of the clinical history to assess prognosis of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction? Eur Heart J. 1989;10:747–52. https://doi.org/10.1093/oxfordjournals.eurheartj.a059559

480. Sarter BH, Finkle JK, Gerszten RE, Buxton AE. What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction? Circulation. 2017;2018(138):e272–e391. https://doi.org/10.1161/CIR.0000000000000549

481. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2017;2018(138):e272–e391. https://doi.org/10.1161/CIR.0000000000000549

482. Friedman DJ, Al-Khatib SM, Zeitler EP, Han J, Bardy GH, Poole JE, et al. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: a pooled analysis of 4 randomized controlled trials. Am Heart J. 2017;191:21–9. https://doi.org/10.1016/j.ahj.2017.06.002

483. Tung R, Vaseghi M, Frankel DS, Vergara P, Di Biase L, Nagashima K, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group Study. Heart Rhythm. 2015;12:1997–2007. https://doi.org/10.1016/j.hrthm.2015.05.036

484. Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ, et al. Seattle heart failure and proportional
risk models predict benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol. 2017;69:2606-18. https://doi.org/10.1016/j.jacc.2017.03.568

485. Kumar S, Androulakis AF, Sellal JM, Maury P, Gandjbakhch E, Waintraub X, et al. Multicenter experience with catheter ablation for ventricular tachycardia in Lamin A/C cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9(8):1-11. e004357.

486. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424-33. https://doi.org/10.1161/CIRCULATIONAHA.105.584102

487. Santangeli P, Muser D, Zado ES, Magnani S, Khetpal S, Hutchinson MD, et al. Acute hemodynamic decompensation during catheter ablation of scar-related ventricular tachycardia: incidence, predictors, and impact on mortality. Circ Arrhythm Electrophysiol. 2015;8:68-75. https://doi.org/10.1161/CIRCEP.114.002155

488. Vakil KP, Roukoz H, Tung R, Levy WC, Anand IS, Shivkumar K, et al. Mortality prediction using a modified Seattle Heart Failure Model may improve patient selection for ventricular tachycardia ablation. Am Heart J. 2015;170:1099-104. https://doi.org/10.1016/j.ahj.2015.09.008

489. Santangeli P, Frankel DS, Tung R, Vaseghi M, Sauer WH, Early TWS, et al. mortality after catheter ablation of ventricular tachycardia in patients with structural heart disease. J Am Coll Cardiol. 2017;69:2105-15. https://doi.org/10.1016/j.jacc.2017.02.044

490. Frankel DS, Tung R, Santangeli P, Tzou WS, Vaseghi M, Di Biase L, et al. Sex and catheter ablation for ventricular tachycardia: an International Ventricular Tachycardia Ablation. Center Collaborative Group Study. JAMA Cardiol. 2016;1:938-44. https://doi.org/10.1001/jamacardio.2016.2361

491. Tzou WS, Tung R, Frankel DS, Vaseghi M, Bunch TJ, Di Biase L, et al. Ventricular tachycardia ablation in severe heart failure: an International Ventricular Tachycardia Ablation Center Collaboration Analysis. Circ Arrhythm Electrophysiol. 2017;10. https://doi.org/10.1161/CIRCEP.116.004494

492. Vaseghi M, Hu TY, Tung R, Vergara P, Frankel DS, Di Biase L, et al. Outcomes of catheter ablation of ventricular tachycardia based on etiology in nonischemic heart disease: an International Ventricular Tachycardia Ablation Center Collaborative study. JACC Clin Electrophysiol. 2018;4:1141-50. https://doi.org/10.1016/j.jacep.2018.05.007

493. Briceno DF, Romero J, Villablanca PA, Londono A, Diaz JC, Maraj I, et al. Long-term outcomes of different ablation strategies for ventricular tachycardia in patients with structural heart disease: systematic review and meta-analysis. Europace. 2018;20:104-15. 10.1093/europace/eux109

494. Papageorgiou N, Providencia R, Bronis K, Dechering DG, Srinivasan N, Eckardt L, et al. Catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis: a systematic review. Europace. 2018;20:682-91. https://doi.org/10.1093/europace/eux077

495. Avila P, Perez-David E, Izquierdo M, Rojas-Gonzalez A, Sanchez-Gomez JM, Ledesma-Carbayo MJ, et al. Scar extension measured by magnetic resonance-based signal intensity mapping predicts ventricular tachycardia recurrence after substrate ablation in patients with previous myocardial infarction. JACC Clin Electrophysiol. 2015;1:353-65. https://doi.org/10.1016/j.jacep.2015.07.006

496. Berruezo A, Acosta J, Fernandez-Armenta J, Pedrote A, Barrera A, Arana-Rueda E, et al. Safety, long-term outcomes and predictors of recurrence after first-line combined endoe epicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study. Europace. 2017;19:607-16.

497. Santangeli P, Zado ES, Supple GE, Haqqani HM, Garcia FC, Tschabrunn CM, et al. Long-term outcome with catheter ablation

of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8:1413-21. https://doi.org/10.1161/CIRCEP.115.003562

498. Dalal D, Jain R, Tandri H, Dong J, Eid SM, Prakasa K, et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007;50:432-40. https://doi.org/10.1016/j.jacc.2007.03.049

499. Fernandez-Armenta J, Andreu D, Penela D, Trucco E, Cipolletta L, Arbelo E, et al. Sinus rhythm detection of conducting channels and ventricular tachycardia isthmus in arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2014;11:747-54. https://doi.org/10.1016/j.hrthm.2014.02.016

500. Oloriz T, Silberbauer J, Maccabelli G, Mizuno H, Baratto F, Kirubakaran S, et al. Catheter ablation of ventricular arrhythmia in nonischemic cardiomyopathy: anteroseptal versus inferolateral scar sub-types. Circ Arrhythm Electrophysiol. 2014;7:414-23. https://doi.org/10.1161/CIRCEP.114.001568

501. Ghanbari H, Baser K, Yokokawa M, Stevenson W, Della Bella P, Vergara P, et al. Noninducibility in postinfarction ventricular tachycardia as an end point for ventricular tachycardia ablation and its effects on outcomes: a meta-analysis. Circ Arrhythm Electrophysiol. 2014;7:e677-83. https://doi.org/10.1161/CIRCEP.113.001404

502. Yokokawa M, Kim HM, Baser K, Stevenson W, Nagashima K, Della Bella P, et al. Predictive value of programmed ventricular stimulation after catheter ablation of post-infarction ventricular tachycardia. J Am Coll Cardiol. 2015;65:1954-9. https://doi.org/10.1016/j.jacc.2015.02.058

503. Frankel DS, Mountantonakis SE, Zado ES, Anter E, Bala R, Cooper JM, et al. Noninvasive programmed ventricular stimulation early after ventricular tachycardia ablation to predict risk of late recurrence. J Am Coll Cardiol. 2012;59:1529-35. https://doi.org/10.1016/j.jacc.2012.01.026

504. Oloriz T, Baratto F, Trevisi N, Barbaro M, Bisceglia C, D'Angelo G, et al. Defining the outcome of ventricular tachycardia ablation: timing and value of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2018;11:e005602. https://doi.org/10.1161/CIRCEP.117.005602

505. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357:2657-65. https://doi.org/10.1056/NEJMoa065457

506. Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacretaz E, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375:31-40. https://doi.org/10.1016/S0140-6736(09)61755-4

507. Tilz RR, Kuck K-H, Kääb S, Wegscheider K, Thiem A, Wenzel B, et al. Rationale and design of BERLIN VT study: a multicenter randomised trial comparing preventive versus deferred ablation of ventricular tachycardia. BMJ Open. 2019;9:e022910. https://doi.org/10.1136/bmjopen-2018-022910

508. Kuck K-H, Tilz RR, Deneke T, Hoffmann BA, Ventura R, Hansen PS, et al. Impact of substrate modification by catheter ablation on implantable cardioverter-defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: results from the multicenter randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol. 2017;10. https://doi.org/10.1161/CIRCEP.116.004422

509. Dukes JW, Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, et al. Ventricular ectopy as a predictor of heart failure and death. J Am Coll Cardiol. 2015;66:101-9. https://doi.org/10.1016/j.jacc.2015.04.062
510. Yokokawa M, Good E, Crawford T, Chugh A, Pelosi F Jr, Latchamsetty R, et al. Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes. Heart Rhythm. 2013;10:172-5. https://doi.org/10.1016/j.hrthm.2012.10.011

511. Carballeira Pol L, Deyell MW, Frankel DS, Benhayon D, Squara F, Chik W, et al. Ventricular premature depolarization QRS duration as a new marker of risk for the development of ventricular premature depolarization-induced cardiomyopathy. Heart Rhythm. 2014;11:299-306. https://doi.org/10.1016/j.hrthm.2013.10.055

512. Niwano S, Wakisaka Y, Niwano H, Fukaya H, Kurokawa S, Kiryu M, et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart. 2009;95:1230-7. https://doi.org/10.1136/hrt.2008.159558

513. Lin C-Y, Chang S-L, Lin Y-J, Lo L-W, Chung F-P, Chen Y-Y, et al. Long-term outcome of multiform premature ventricular complexes in structurally normal heart. Int J Cardiol. 2015;180:80-5. https://doi.org/10.1016/j.ijcard.2014.11.110

514. Del carpio munoz F, Syed FF, Noheria A, Cha Y-M, Friedman PA, Hammill SC, et al. Characteristics of premature ventricular complexes as correlates of reduced left ventricular systolic function: study of the burden, duration, coupling interval, morphology and site of origin of PVCs. J Cardiovasc Electrophysiol. 2011;22:791-8. https://doi.org/10.1111/j.1540-8167.2011.02021.x

515. Zhong LI, Lee Y-H, Huang X-M, Asirvatham SJ, Shen W-K, Friedman PA, et al. Relative efficacy of catheter ablation vs anti-arrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study. Heart Rhythm. 2014;11:187-93. https://doi.org/10.1016/j.hrthm.2013.10.033

516. Olgun H, Yokokawa M, Baman T, Kim HM, Armstrong W, Good E, et al. The role of interpolation in PVC-induced cardiomyopathy. Heart Rhythm. 2011;8:1046-9. https://doi.org/10.1016/j.hrthm.2011.02.034

517. Leenhardt A, Glaser E, Burguera M, Nurnberg M, Maison-Blanche P, Coumel P. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation. 1994;89:206-15. https://doi.org/10.1161/01.CIR.89.1.206

518. Prystowsky EN, Padanilam BJ, Joshi S, Fogel RI. Ventricular arrhythmias in the absence of structural heart disease. J Am Coll Cardiol. 2012;59:1733-44. https://doi.org/10.1016/j.jacc.2012.01.036

519. Pappone C, Vicedomini G, Manguso F, Saviano M, Baldi M, Pappone A, et al. Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients. Circulation. 2014;130:811-9. https://doi.org/10.1161/CIRCULATIONAHA.114.011154

520. Timmermans C, Smeets JL, Rodriguez L-M, Vrouchos G, van den Dool A, Wellens HJJ. Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1995;76:492-4. https://doi.org/10.1016/S0002-9149(99)80136-2

521. Katritsis DG, Boriani G, Cosio FG, Hindricks G, Jais P, European JME, et al. Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiología (SOLAECE). Europace. 2017;19:465-511. https://doi.org/10.1093/europace/euw301

522. Katritsis DG, Boriani G, Cosio FG, Hindricks G, Jais P, European JME, et al. Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiología (SOLAECE). Eur Heart J. 2018;39:1442-5. https://doi.org/10.1093/eurheartj/ehw455

523. Wackel P, Irving C, Webber S, Beerman L, Arora G. Risk stratification in Wolff-Parkinson-White syndrome: the correlation between noninvasive and invasive testing in pediatric patients. Pacing Clin Electrophysiol. 2012;35: 1451-7. https://doi.org/10.1111/j.1540-8159.2012.03518.x

524. Spar DS, Silver ES, Hordof AJ, Liberman L. Relation of the utility of exercise testing for risk assessment in pediatric patients with ventricular preexcitation to pathway location. Am J Cardiol. 2012;109:1011-4. https://doi.org/10.1016/j.amjca rd.2011.11.030

525. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJBlomstrom-Lundqvist C, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720.

526. Medi C, Kalman JM, Haqqani H, Vohra JK, Morton JB, Sparks PB, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol. 2009;53:1791-7. https://doi.org/10.1016/j.jacc.2009.02.014

527. Arnar DO, Mairesse GH, Boriani G, Calkins H, Chin A, Coats A, et al. Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). Europace. 2019. https://doi.org/10.1093/europace/euz046. [Epub ahead of print].

**How to cite this article:** Nielsen JC, Lin Y-J, de Oliveira Figueiredo MJ, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. *J Arrhythmia*. 2020;36:553-607. https://doi.org/10.1002/joa3.12338

APPENDIX

ESC Scientific Document Group: Alfred E. Buxton: Department of Medicine, The Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Gonzalo Calvimontes: Asociacion Guatemalteca de Cardiologia, Guatemala; Tze-Fan Chao: Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taiwan; Lars Eckardt: Department for Cardiology, Electrophysiology, University Hospital Münster, Münster, Germany; Heidi Estner: Department of Medicine, I, University Hospital Munich, Ludwig-Maximilians University, Munich, Germany; Anne M. Gillis: University of Calgary - Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada; Rodrigo Isa: Clinica RedSalud Vitacura and Hospital el Carmen de Maipú, Santiago, Chile; Josef Kautzner: Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Philippe Maury: Rangueil University Hospital, Toulouse, France; Joshua D. Moss: Department of Cardiac Electrophysiology,
University of California San Francisco, San Francisco, USA; Gi-Byung Nam: Division of Cardiology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Republic of Korea; Brian Olshansky: University of Iowa Carver College of Medicine, Iowa City, USA; Luis Fernando Pava Molano: Fundación Valle del Lili, Cali, Colombia; Mauricio Pimentel: Cardiology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil; Mukund Prabhu: Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India; Wendy S. Tzou: Department of Cardiology/Cardiac Electrophysiology, University of Colorado Anschutz Medical Campus, Aurora,

USA; Philipp Sommer: Clinic for Electrophysiology, Herz- und Diabeteszentrum, Clinic for Electrophysiology, Ruhr-Universität Bochum, Bad Oeynhausen, Germany; Janice Swampillai: Waikato Hospital, Hamilton, New Zealand; Alejandro Vidal: Division of Cardiology, McGill University Health Center, Montreal, Canada; Thomas Deneke (Reviewer Coordinator): Clinic for Cardiology II (Interventional Electrophysiology), Heart Center Bad Neustadt, Bad Neustadt a.d. Saale, Germany; Gerhard Hindricks, Department of Electrophysiology, Leipzig Heart Center at University of Leipzig, Leipzig, Germany; Christophe Leclercq (ESC-CPG representative): Univ Rennes, CHU Rennes, INSERM, Rennes, France.